51
|
Wang T, Huang T, Zheng Y, Rood J, Bray GA, Sacks FM, Qi L. Genetic variation of fasting glucose and changes in glycemia in response to 2-year weight-loss diet intervention: the POUNDS LOST trial. Int J Obes (Lond) 2016; 40:1164-9. [PMID: 27113490 PMCID: PMC4935586 DOI: 10.1038/ijo.2016.41] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2015] [Revised: 01/14/2016] [Accepted: 01/28/2016] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Weight-loss intervention through diet modification has been widely used to improve obesity-related hyperglycemia; however, little is known about whether genetic variation modifies the intervention effect. We examined the interaction between weight-loss diets and genetic variation of fasting glucose on changes in glycemic traits in a dietary intervention trial. RESEARCH DESIGN AND METHODS The Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial is a randomized, controlled 2-year weight-loss trial. We assessed overall genetic variation of fasting glucose by calculating a genetic risk score (GRS) based on 14 fasting glucose-associated single nucleotide polymorphisms, and examined the progression in fasting glucose and insulin levels, and insulin resistance and insulin sensitivity in 733 adults from this trial. RESULTS The GRS was associated with 6-month changes in fasting glucose (P<0.001), fasting insulin (P=0.042), homeostasis model assessment of insulin resistance (HOMA-IR, P=0.009) and insulin sensitivity (HOMA-S, P=0.043). We observed significant interaction between the GRS and dietary fat on 6-month changes in fasting glucose, HOMA-IR and HOMA-S after multivariable adjustment (P-interaction=0.007, 0.045 and 0.028, respectively). After further adjustment for weight loss, the interaction remained significant on change in fasting glucose (P=0.015). In the high-fat diet group, participants in the highest GRS tertile showed increased fasting glucose, whereas participants in the lowest tertile showed decreased fasting glucose (P-trend <0.001); in contrast, the genetic association was not significant in the low-fat diet group (P-trend=0.087). CONCLUSIONS Our data suggest that participants with a higher genetic risk may benefit more by eating a low-fat diet to improve glucose metabolism.
Collapse
Affiliation(s)
- Tiange Wang
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Tao Huang
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Yan Zheng
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Jennifer Rood
- Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, LA, USA
| | - George A. Bray
- Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, LA, USA
| | - Frank M. Sacks
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Lu Qi
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| |
Collapse
|
52
|
Marmugi A, Parnis J, Chen X, Carmichael L, Hardy J, Mannan N, Marchetti P, Piemonti L, Bosco D, Johnson P, Shapiro JAM, Cruciani-Guglielmacci C, Magnan C, Ibberson M, Thorens B, Valdivia HH, Rutter GA, Leclerc I. Sorcin Links Pancreatic β-Cell Lipotoxicity to ER Ca2+ Stores. Diabetes 2016; 65:1009-21. [PMID: 26822088 PMCID: PMC4806657 DOI: 10.2337/db15-1334] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 01/18/2016] [Indexed: 01/02/2023]
Abstract
Preserving β-cell function during the development of obesity and insulin resistance would limit the worldwide epidemic of type 2 diabetes. Endoplasmic reticulum (ER) calcium (Ca(2+)) depletion induced by saturated free fatty acids and cytokines causes β-cell ER stress and apoptosis, but the molecular mechanisms behind these phenomena are still poorly understood. Here, we demonstrate that palmitate-induced sorcin downregulation and subsequent increases in glucose-6-phosphatase catalytic subunit-2 (G6PC2) levels contribute to lipotoxicity. Sorcin is a calcium sensor protein involved in maintaining ER Ca(2+) by inhibiting ryanodine receptor activity and playing a role in terminating Ca(2+)-induced Ca(2+) release. G6PC2, a genome-wide association study gene associated with fasting blood glucose, is a negative regulator of glucose-stimulated insulin secretion (GSIS). High-fat feeding in mice and chronic exposure of human islets to palmitate decreases endogenous sorcin expression while levels of G6PC2 mRNA increase. Sorcin-null mice are glucose intolerant, with markedly impaired GSIS and increased expression of G6pc2 Under high-fat diet, mice overexpressing sorcin in the β-cell display improved glucose tolerance, fasting blood glucose, and GSIS, whereas G6PC2 levels are decreased and cytosolic and ER Ca(2+) are increased in transgenic islets. Sorcin may thus provide a target for intervention in type 2 diabetes.
Collapse
Affiliation(s)
- Alice Marmugi
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K
| | - Julia Parnis
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K
| | - Xi Chen
- Center for Arrhythmia Research, University of Michigan, Ann Arbor, MI
| | - LeAnne Carmichael
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K
| | - Julie Hardy
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K
| | - Naila Mannan
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K
| | - Piero Marchetti
- Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
| | - Lorenzo Piemonti
- Diabetes Research Institute (HSR-DRI), San Raffaele Scientific Institute, Milan, Italy
| | - Domenico Bosco
- Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Paul Johnson
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, U.K
| | - James A M Shapiro
- Clinical Islet Laboratory and Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
| | | | - Christophe Magnan
- Unit of Functional and Adaptive Biology, Paris Diderot University-Paris 7, Paris, France
| | - Mark Ibberson
- Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Bernard Thorens
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
| | - Héctor H Valdivia
- Center for Arrhythmia Research, University of Michigan, Ann Arbor, MI
| | - Guy A Rutter
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K.
| | - Isabelle Leclerc
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Imperial College London, London, U.K.
| |
Collapse
|
53
|
Wang S, Zhao JH, An P, Guo X, Jensen RA, Marten J, Huffman JE, Meidtner K, Boeing H, Campbell A, Rice KM, Scott RA, Yao J, Schulze MB, Wareham NJ, Borecki IB, Province MA, Rotter JI, Hayward C, Goodarzi MO, Meigs JB, Dupuis J. General Framework for Meta-Analysis of Haplotype Association Tests. Genet Epidemiol 2016; 40:244-52. [PMID: 27027517 PMCID: PMC4869684 DOI: 10.1002/gepi.21959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 11/03/2015] [Accepted: 12/14/2015] [Indexed: 11/24/2022]
Abstract
For complex traits, most associated single nucleotide variants (SNV) discovered to date have a small effect, and detection of association is only possible with large sample sizes. Because of patient confidentiality concerns, it is often not possible to pool genetic data from multiple cohorts, and meta‐analysis has emerged as the method of choice to combine results from multiple studies. Many meta‐analysis methods are available for single SNV analyses. As new approaches allow the capture of low frequency and rare genetic variation, it is of interest to jointly consider multiple variants to improve power. However, for the analysis of haplotypes formed by multiple SNVs, meta‐analysis remains a challenge, because different haplotypes may be observed across studies. We propose a two‐stage meta‐analysis approach to combine haplotype analysis results. In the first stage, each cohort estimate haplotype effect sizes in a regression framework, accounting for relatedness among observations if appropriate. For the second stage, we use a multivariate generalized least square meta‐analysis approach to combine haplotype effect estimates from multiple cohorts. Haplotype‐specific association tests and a global test of independence between haplotypes and traits are obtained within our framework. We demonstrate through simulation studies that we control the type‐I error rate, and our approach is more powerful than inverse variance weighted meta‐analysis of single SNV analysis when haplotype effects are present. We replicate a published haplotype association between fasting glucose‐associated locus (G6PC2) and fasting glucose in seven studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium and we provide more precise haplotype effect estimates.
Collapse
Affiliation(s)
- Shuai Wang
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - Jing Hua Zhao
- MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Ping An
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Xiuqing Guo
- Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, California, United States of America
| | - Richard A Jensen
- Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, United States of America.,Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Jonathan Marten
- MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom
| | - Jennifer E Huffman
- MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom
| | - Karina Meidtner
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Archie Campbell
- Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetic and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, United Kindom
| | - Kenneth M Rice
- Department of Biostatistics, University of Washington, Seattle, Washington, United States of America
| | - Robert A Scott
- MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Jie Yao
- Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, California, United States of America
| | - Matthias B Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.,German Center for Diabetes Research (DZD), Germany
| | - Nicholas J Wareham
- MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Ingrid B Borecki
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Michael A Province
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Jerome I Rotter
- Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, California, United States of America
| | - Caroline Hayward
- Department of Medicine, University of Washington, Seattle, Washington, United States of America.,Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetic and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, United Kindom
| | - Mark O Goodarzi
- Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
| | - James B Meigs
- General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.,Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
| | - Josée Dupuis
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.,National Heart, Lung, Blood Institute (NHLBI), Framingham Heart Study, Framingham, Massachusetts, United States of America
| |
Collapse
|
54
|
Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol Med 2016; 48:e220. [PMID: 26964836 PMCID: PMC4892885 DOI: 10.1038/emm.2016.7] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 12/09/2015] [Accepted: 12/11/2015] [Indexed: 12/12/2022] Open
Abstract
Type 2 diabetes (T2DM) is a common complex metabolic disorder that has a strong genetic predisposition. During the past decade, progress in genetic association studies has enabled the identification of at least 75 independent genetic loci for T2DM, thus allowing a better understanding of the genetic architecture of T2DM. International collaborations and large-scale meta-analyses of genome-wide association studies have made these achievements possible. However, whether the identified common variants are causal is largely unknown. In addition, the detailed mechanism of how these genetic variants exert their effect on the pathogenesis of T2DM requires further investigation. Currently, there are ongoing large-scale sequencing studies to identify rare, functional variants for T2DM. Environmental factors also have a crucial role in the development of T2DM. These could modulate gene expression via epigenetic mechanisms, including DNA methylation, histone modification and microRNA regulation. There is evidence that epigenetic changes are important in the development of T2DM. Recent studies have identified several DNA methylation markers of T2DM from peripheral blood and pancreatic islets. In this review, we will briefly summarize the recent progress in the genetic and epigenetic research on T2DM and discuss how environmental factors, genetics and epigenetics can interact in the pathogenesis of T2DM.
Collapse
Affiliation(s)
- Soo Heon Kwak
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - Kyong Soo Park
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
| |
Collapse
|
55
|
Paul L, Walker EM, Drosos Y, Cyphert HA, Neale G, Stein R, South J, Grosveld G, Herrera PL, Sosa-Pineda B. Lack of Prox1 Downregulation Disrupts the Expansion and Maturation of Postnatal Murine β-Cells. Diabetes 2016; 65:687-98. [PMID: 26631740 PMCID: PMC4764148 DOI: 10.2337/db15-0713] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 11/20/2015] [Indexed: 12/18/2022]
Abstract
Transcription factor expression fluctuates during β-cell ontogeny, and disruptions in this pattern can affect the development or function of those cells. Here we uncovered that murine endocrine pancreatic progenitors express high levels of the homeodomain transcription factor Prox1, whereas both immature and mature β-cells scarcely express this protein. We also investigated if sustained Prox1 expression is incompatible with β-cell development or maintenance using transgenic mouse approaches. We discovered that Prox1 upregulation in mature β-cells has no functional consequences; in contrast, Prox1 overexpression in immature β-cells promotes acute fasting hyperglycemia. Using a combination of immunostaining and quantitative and comparative gene expression analyses, we determined that Prox1 upregulation reduces proliferation, impairs maturation, and enables apoptosis in postnatal β-cells. Also, we uncovered substantial deficiency in β-cells that overexpress Prox1 of the key regulator of β-cell maturation MafA, several MafA downstream targets required for glucose-stimulated insulin secretion, and genes encoding important components of FGF signaling. Moreover, knocking down PROX1 in human EndoC-βH1 β-cells caused increased expression of many of these same gene products. These and other results in our study indicate that reducing the expression of Prox1 is beneficial for the expansion and maturation of postnatal β-cells.
Collapse
Affiliation(s)
- Leena Paul
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN
| | - Emily M Walker
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| | - Yiannis Drosos
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN
| | - Holly A Cyphert
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| | - Geoffrey Neale
- Hartwell Center for Bioinformatics & Biotechnology, St. Jude Children's Research Hospital, Memphis, TN
| | - Roland Stein
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| | - Jack South
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN
| | - Gerard Grosveld
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN
| | - Pedro L Herrera
- Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Beatriz Sosa-Pineda
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
| |
Collapse
|
56
|
Genetic and clinical variables identify predictors for chronic kidney disease in type 2 diabetes. Kidney Int 2016; 89:411-20. [PMID: 26806836 DOI: 10.1016/j.kint.2015.09.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 09/24/2015] [Accepted: 09/24/2015] [Indexed: 01/13/2023]
Abstract
Type 2 diabetes and chronic kidney disease (CKD) may share common risk factors. Here we used a 3-stage procedure to discover novel predictors of CKD by repeatedly applying a stepwise selection based on the Akaike information criterion to subsamples of a prospective complete-case cohort of 2755 patients. This cohort encompassed 25 clinical variables and 36 genetic variants associated with type 2 diabetes, obesity, or fasting plasma glucose. We compared the performance of the clinical, genetic, and clinico-genomic models and used net reclassification improvement to evaluate the impact of top selected genetic variants to the clinico-genomic model. Associations of selected genetic variants with CKD were validated in 2 independent cohorts followed by meta-analyses. Among the top 6 single-nucleotide polymorphisms selected from clinico-genomic data, three (rs478333 of G6PC2, rs7754840 and rs7756992 of CDKAL1) contributed toward the improvement of prediction performance. The variant rs478333 was associated with rapid decline (over 4% per year) in estimated glomerular filtration rate. In a meta-analysis of 2 replication cohorts, the variants rs478333 and rs7754840 showed significant associations with CKD after adjustment for conventional risk factors. Thus, this novel 3-stage approach to a clinico-genomic data set identified 3 novel genetic predictors of CKD in type 2 diabetes. This method can be applied to similar data sets containing clinical and genetic variables to select predictors for clinical outcomes.
Collapse
|
57
|
Bray MS, Loos RJF, McCaffery JM, Ling C, Franks PW, Weinstock GM, Snyder MP, Vassy JL, Agurs-Collins T. NIH working group report-using genomic information to guide weight management: From universal to precision treatment. Obesity (Silver Spring) 2016; 24:14-22. [PMID: 26692578 PMCID: PMC4689320 DOI: 10.1002/oby.21381] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 10/16/2015] [Accepted: 10/17/2015] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Precision medicine utilizes genomic and other data to optimize and personalize treatment. Although more than 2,500 genetic tests are currently available, largely for extreme and/or rare phenotypes, the question remains whether this approach can be used for the treatment of common, complex conditions like obesity, inflammation, and insulin resistance, which underlie a host of metabolic diseases. METHODS This review, developed from a Trans-NIH Conference titled "Genes, Behaviors, and Response to Weight Loss Interventions," provides an overview of the state of genetic and genomic research in the area of weight change and identifies key areas for future research. RESULTS Although many loci have been identified that are associated with cross-sectional measures of obesity/body size, relatively little is known regarding the genes/loci that influence dynamic measures of weight change over time. Although successful short-term weight loss has been achieved using many different strategies, sustainable weight loss has proven elusive for many, and there are important gaps in our understanding of energy balance regulation. CONCLUSIONS Elucidating the molecular basis of variability in weight change has the potential to improve treatment outcomes and inform innovative approaches that can simultaneously take into account information from genomic and other sources in devising individualized treatment plans.
Collapse
Affiliation(s)
- Molly S Bray
- Department of Nutritional Sciences, The University of Texas at AustinAustin, Texas, USA
| | - Ruth JF Loos
- Department of Preventive Medicine, The Charles Bronfman Institute for Personalized Medicine, The Mindich Child Health and Development Institute, The Icahn School of Medicine at Mount SinaiNew York City, New York, USA
| | - Jeanne M McCaffery
- Department of Psychiatry and Human Behavior, Weight Control and Diabetes Research Center, The Alpert Medical School of Brown University/The Miriam HospitalProvidence, Rhode Island, USA
| | - Charlotte Ling
- Department of Clinical Sciences, Skåne University HospitalMalmö, Sweden
| | - Paul W Franks
- Department of Clinical Sciences, Skåne University HospitalMalmö, Sweden
| | | | - Michael P Snyder
- Department of Genetics, Stanford University School of MedicineStanford, California, USA
| | - Jason L Vassy
- Division of General Medicine, Brigham and Women's Hospital and Harvard Medical SchoolBoston, Massachusetts, USA
| | - Tanya Agurs-Collins
- Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of HealthBethesda, Maryland, USA.
| | | |
Collapse
|
58
|
Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SEH, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer 2015; 22:545-59. [PMID: 26099684 DOI: 10.1530/erc-15-0029] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/15/2015] [Indexed: 12/18/2022]
Abstract
Type 2 diabetes (T2D) has been suggested to be a risk factor for multiple myeloma (MM), but the relationship between the two traits is still not well understood. The aims of this study were to evaluate whether 58 genome-wide-association-studies (GWAS)-identified common variants for T2D influence the risk of developing MM and to determine whether predictive models built with these variants might help to predict the disease risk. We conducted a case-control study including 1420 MM patients and 1858 controls ascertained through the International Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32-2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76-0.85). Interestingly, a prediction model including those T2D-related variants associated with the risk of MM showed a significantly improved discriminatory ability to predict the disease when compared to a model without genetic information (area under the curve (AUC)=0.645 vs AUC=0.629; P=4.05×10(-) (06)). A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348 and NOTCH2rs10923931 variants (Pinteraction=0.001 and 0.0004, respectively). Men carrying the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a significantly decreased risk of MM whereas an opposite but not significant effect was observed in women (ORM=0.71 and ORM=0.66 vs ORW=1.22 and ORW=1.15, respectively). These results suggest that TD2-related variants may influence the risk of developing MM and their genotyping might help to improve MM risk prediction models.
Collapse
Affiliation(s)
- Rafael Ríos
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Carmen Belén Lupiañez
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Daniele Campa
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Alessandro Martino
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Joaquin Martínez-López
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Manuel Martínez-Bueno
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Judit Varkonyi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Ramón García-Sanz
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Krzysztof Jamroziak
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Charles Dumontet
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Andrés Jerez Cayuela
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Marzena Wętek
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Stephano Landi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Anna Maria Rossi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Fabienne Lesueur
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Rui Manuel Reis
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Victor Moreno
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Herlander Marques
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Artur Jurczyszyn
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Vibeke Andersen
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Ulla Vogel
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Gabriele Buda
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Enrico Orciuolo
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Svend E H Jacobsen
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Mario Petrini
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Annette J Vangsted
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Federica Gemignani
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Federico Canzian
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Manuel Jurado
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Juan Sainz
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| |
Collapse
|
59
|
Abstract
Individual differences in sensitivity to insulin contribute to disease susceptibility including diabetes and metabolic syndrome. Cellular responses to insulin are well studied. However, which steps in these response pathways differ across individuals remains largely unknown. Such knowledge is needed to guide more precise therapeutic interventions. Here, we studied insulin response and found extensive individual variation in the activation of key signaling factors, including ERK whose induction differs by more than 20-fold among our subjects. This variation in kinase activity is propagated to differences in downstream gene expression response to insulin. By genetic analysis, we identified cis-acting DNA variants that influence signaling response, which in turn affects downstream changes in gene expression and cellular phenotypes, such as protein translation and cell proliferation. These findings show that polymorphic differences in signal transduction contribute to individual variation in insulin response, and suggest kinase modulators as promising therapeutics for diseases characterized by insulin resistance.
Collapse
Affiliation(s)
| | | | - Vivian G Cheung
- Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA Howard Hughes Medical Institute, Chevy Chase, MD, USA Departments of Pediatrics and Genetics, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
60
|
Wall ML, Pound LD, Trenary I, O'Brien RM, Young JD. Novel stable isotope analyses demonstrate significant rates of glucose cycling in mouse pancreatic islets. Diabetes 2015; 64:2129-37. [PMID: 25552595 PMCID: PMC4439557 DOI: 10.2337/db14-0745] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2014] [Accepted: 12/20/2014] [Indexed: 11/20/2022]
Abstract
A polymorphism located in the G6PC2 gene, which encodes an islet-specific glucose-6-phosphatase catalytic subunit, is the most important common determinant of variations in fasting blood glucose (FBG) levels in humans. Studies of G6pc2 knockout (KO) mice suggest that G6pc2 represents a negative regulator of basal glucose-stimulated insulin secretion (GSIS) that acts by hydrolyzing glucose-6-phosphate (G6P), thereby reducing glycolytic flux. However, this conclusion conflicts with the very low estimates for the rate of glucose cycling in pancreatic islets, as assessed using radioisotopes. We have reassessed the rate of glucose cycling in pancreatic islets using a novel stable isotope method. The data show much higher levels of glucose cycling than previously reported. In 5 mmol/L glucose, islets from C57BL/6J chow-fed mice cycled ∼16% of net glucose uptake. The cycling rate was further increased at 11 mmol/L glucose. Similar cycling rates were observed using islets from high fat-fed mice. Importantly, glucose cycling was abolished in G6pc2 KO mouse islets, confirming that G6pc2 opposes the action of the glucose sensor glucokinase by hydrolyzing G6P. The demonstration of high rates of glucose cycling in pancreatic islets explains why G6pc2 deletion enhances GSIS and why variants in G6PC2 affect FBG in humans.
Collapse
Affiliation(s)
- Martha L Wall
- Department of Chemical and Biomolecular Engineering, Vanderbilt School of Engineering, Nashville, TN
| | - Lynley D Pound
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| | - Irina Trenary
- Department of Chemical and Biomolecular Engineering, Vanderbilt School of Engineering, Nashville, TN
| | - Richard M O'Brien
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| | - Jamey D Young
- Department of Chemical and Biomolecular Engineering, Vanderbilt School of Engineering, Nashville, TN Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN
| |
Collapse
|
61
|
Wang J, Yan G, Zhang J, Gao K, Zhang M, Li L, Wang Y, Wang Q, Zhai Y, You H, Ren Y, Wang B, Hu D. Association of LRP5, TCF7L2, and GCG variants and type 2 diabetes mellitus as well as fasting plasma glucose and lipid metabolism indexes. Hum Immunol 2015; 76:339-43. [PMID: 25863010 DOI: 10.1016/j.humimm.2015.03.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Revised: 01/19/2015] [Accepted: 03/11/2015] [Indexed: 12/27/2022]
Abstract
Recent data puts WNT signaling pathway in a pivotal role in regulating pancreas development as well as islet function, insulin production and secretion. The key effectors in the WNT signaling pathway are low-density lipoprotein receptor-related protein 5 (LRP5), transcription factor 7-like 2 (TCF7L2), and downstream-regulated glucagon (GCG). Our previous studies suggest that the WNT signaling pathway plays a significant role in risk of type 2 diabetes mellitus (T2DM) in Chinese population. The main purpose of the present study was to investigate the associations of single nucleotide polymorphisms (SNPs) in LRP5, TCF7L2 and glucagon (GCG) and quantitative traits in a healthy population. We used tag SNP to screen candidate SNPs for LRP5 and GCG; for TCF7L2, used the confirmed SNP rs11196218. A total of 1842 patients with T2DM and 7777 healthy controls underwent genotyping for the SNPs. We found a significant association of rs3758644 in LRP5 and fasting plasma glucose (p=0.006), and rs11196218 in TCF7L2 and triglycerides level (p=0.004). Among the SNPs in LRP5, TCF7L2, and GCG analyzed, only rs3758644 of LRP5 and rs11196218 of TCF7L2 were significantly associated with fasting plasma glucose and triglycerides index, respectively, in a healthy population.
Collapse
Affiliation(s)
- Jinjin Wang
- Department of Traditional Chinese Medicine Prevention, Preventive Medicine Research Evaluation Center, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Guoli Yan
- Department of Traditional Chinese Medicine Prevention, Preventive Medicine Research Evaluation Center, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Jianfeng Zhang
- Henan Armed Police Corps Hospital, Zhengzhou 450000, People's Republic of China.
| | - Kaiping Gao
- Shenzhen University School of Medicine, Shenzhen 518060, People's Republic of China.
| | - Ming Zhang
- Shenzhen University School of Medicine, Shenzhen 518060, People's Republic of China.
| | - Linlin Li
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Yan Wang
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Qian Wang
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Yujia Zhai
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Haifei You
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Yongcheng Ren
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Bingyuan Wang
- Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, People's Republic of China.
| | - Dongsheng Hu
- Shenzhen University School of Medicine, Shenzhen 518060, People's Republic of China.
| |
Collapse
|
62
|
Mahajan A, Sim X, Ng HJ, Manning A, Rivas MA, Highland HM, Locke AE, Grarup N, Im HK, Cingolani P, Flannick J, Fontanillas P, Fuchsberger C, Gaulton KJ, Teslovich TM, Rayner NW, Robertson NR, Beer NL, Rundle JK, Bork-Jensen J, Ladenvall C, Blancher C, Buck D, Buck G, Burtt NP, Gabriel S, Gjesing AP, Groves CJ, Hollensted M, Huyghe JR, Jackson AU, Jun G, Justesen JM, Mangino M, Murphy J, Neville M, Onofrio R, Small KS, Stringham HM, Syvänen AC, Trakalo J, Abecasis G, Bell GI, Blangero J, Cox NJ, Duggirala R, Hanis CL, Seielstad M, Wilson JG, Christensen C, Brandslund I, Rauramaa R, Surdulescu GL, Doney ASF, Lannfelt L, Linneberg A, Isomaa B, Tuomi T, Jørgensen ME, Jørgensen T, Kuusisto J, Uusitupa M, Salomaa V, Spector TD, Morris AD, Palmer CNA, Collins FS, Mohlke KL, Bergman RN, Ingelsson E, Lind L, Tuomilehto J, Hansen T, Watanabe RM, Prokopenko I, Dupuis J, Karpe F, Groop L, Laakso M, Pedersen O, Florez JC, Morris AP, Altshuler D, Meigs JB, Boehnke M, McCarthy MI, Lindgren CM, Gloyn AL. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genet 2015; 11:e1004876. [PMID: 25625282 PMCID: PMC4307976 DOI: 10.1371/journal.pgen.1004876] [Citation(s) in RCA: 86] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Accepted: 11/04/2014] [Indexed: 12/23/2022] Open
Abstract
Genome wide association studies (GWAS) for fasting glucose (FG) and insulin (FI) have identified common variant signals which explain 4.8% and 1.2% of trait variance, respectively. It is hypothesized that low-frequency and rare variants could contribute substantially to unexplained genetic variance. To test this, we analyzed exome-array data from up to 33,231 non-diabetic individuals of European ancestry. We found exome-wide significant (P<5×10-7) evidence for two loci not previously highlighted by common variant GWAS: GLP1R (p.Ala316Thr, minor allele frequency (MAF)=1.5%) influencing FG levels, and URB2 (p.Glu594Val, MAF = 0.1%) influencing FI levels. Coding variant associations can highlight potential effector genes at (non-coding) GWAS signals. At the G6PC2/ABCB11 locus, we identified multiple coding variants in G6PC2 (p.Val219Leu, p.His177Tyr, and p.Tyr207Ser) influencing FG levels, conditionally independent of each other and the non-coding GWAS signal. In vitro assays demonstrate that these associated coding alleles result in reduced protein abundance via proteasomal degradation, establishing G6PC2 as an effector gene at this locus. Reconciliation of single-variant associations and functional effects was only possible when haplotype phase was considered. In contrast to earlier reports suggesting that, paradoxically, glucose-raising alleles at this locus are protective against type 2 diabetes (T2D), the p.Val219Leu G6PC2 variant displayed a modest but directionally consistent association with T2D risk. Coding variant associations for glycemic traits in GWAS signals highlight PCSK1, RREB1, and ZHX3 as likely effector transcripts. These coding variant association signals do not have a major impact on the trait variance explained, but they do provide valuable biological insights. Understanding how FI and FG levels are regulated is important because their derangement is a feature of T2D. Despite recent success from GWAS in identifying regions of the genome influencing glycemic traits, collectively these loci explain only a small proportion of trait variance. Unlocking the biological mechanisms driving these associations has been challenging because the vast majority of variants map to non-coding sequence, and the genes through which they exert their impact are largely unknown. In the current study, we sought to increase our understanding of the physiological pathways influencing both traits using exome-array genotyping in up to 33,231 non-diabetic individuals to identify coding variants and consequently genes associated with either FG or FI levels. We identified novel association signals for both traits including the receptor for GLP-1 agonists which are a widely used therapy for T2D. Furthermore, we identified coding variants at several GWAS loci which point to the genes underlying these association signals. Importantly, we found that multiple coding variants in G6PC2 result in a loss of protein function and lower fasting glucose levels.
Collapse
Affiliation(s)
- Anubha Mahajan
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Xueling Sim
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Hui Jin Ng
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Alisa Manning
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Manuel A. Rivas
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Heather M. Highland
- Human Genetics Center, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
| | - Adam E. Locke
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Niels Grarup
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Hae Kyung Im
- Department of Health Studies, Biostatistics Laboratory, The University of Chicago, Chicago, Illinois, United States of America
| | - Pablo Cingolani
- School of Computer Science, McGill University, Montreal, Quebec, Canada
- McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada
| | - Jason Flannick
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
- Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Pierre Fontanillas
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Christian Fuchsberger
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Kyle J. Gaulton
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Tanya M. Teslovich
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - N. William Rayner
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
- Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom
| | - Neil R. Robertson
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Nicola L. Beer
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Jana K. Rundle
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Jette Bork-Jensen
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Claes Ladenvall
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden
| | - Christine Blancher
- High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - David Buck
- High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Gemma Buck
- High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Noël P. Burtt
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Stacey Gabriel
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Anette P. Gjesing
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Christopher J. Groves
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Mette Hollensted
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jeroen R. Huyghe
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Anne U. Jackson
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Goo Jun
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Johanne Marie Justesen
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Massimo Mangino
- Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom
| | - Jacquelyn Murphy
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Matt Neville
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Robert Onofrio
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Kerrin S. Small
- Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom
| | - Heather M. Stringham
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Ann-Christine Syvänen
- Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Joseph Trakalo
- High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Goncalo Abecasis
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Graeme I. Bell
- Departments of Medicine and Human Genetics, The University of Chicago, Chicago, Illinois, United States of America
| | - John Blangero
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, United States of America
| | - Nancy J. Cox
- Department of Medicine, Section of Genetic Medicine, The University of Chicago, Chicago, Illinois, United States of America
| | - Ravindranath Duggirala
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, United States of America
| | - Craig L. Hanis
- Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
| | - Mark Seielstad
- Blood Systems Research Institute, San Francisco, California, United States of America
- Department of Laboratory Medicine & Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America
| | - James G. Wilson
- Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, United States of America
| | - Cramer Christensen
- Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark
| | - Ivan Brandslund
- Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark
- Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
| | - Rainer Rauramaa
- Foundation for Research in Health, Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
| | - Gabriela L. Surdulescu
- Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom
| | - Alex S. F. Doney
- Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
| | - Lars Lannfelt
- Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden
| | - Allan Linneberg
- Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
| | - Bo Isomaa
- Department of Social Services and Health Care, Jakobstad, Finland
- Folkhälsan Research Centre, Helsinki, Finland
| | - Tiinamaija Tuomi
- Folkhälsan Research Centre, Helsinki, Finland
- Department of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland
| | | | - Torben Jørgensen
- Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
- Faculty of Medicine, University of Aalborg, Aalborg, Denmark
| | - Johanna Kuusisto
- Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland
- Kuopio University Hospital, Kuopio, Finland
| | - Matti Uusitupa
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
| | - Veikko Salomaa
- National Institute for Health and Welfare, Helsinki, Finland
| | - Timothy D. Spector
- Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom
| | - Andrew D. Morris
- Clinical Research Centre, Centre for Molecular Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom
| | - Colin N. A. Palmer
- Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
| | - Francis S. Collins
- Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Karen L. Mohlke
- Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
| | - Richard N. Bergman
- Cedars-Sinai Diabetes and Obesity Research Institute, Los Angeles, California, United States of America
| | - Erik Ingelsson
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Lars Lind
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Jaakko Tuomilehto
- Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia
- Instituto de Investigacion Sanitaria del Hospital Universario LaPaz (IdiPAZ), University Hospital LaPaz, Autonomous University of Madrid, Madrid, Spain
- Center for Vascular Prevention, Danube University Krems, Krems, Austria
- Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland
| | - Torben Hansen
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - Richard M. Watanabe
- Department of Physiology & Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
- Diabetes and Obesity Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
| | - Inga Prokopenko
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, United Kingdom
| | - Josee Dupuis
- National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts, United States of America
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - Fredrik Karpe
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, United Kingdom
| | - Leif Groop
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden
| | - Markku Laakso
- Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland
- Kuopio University Hospital, Kuopio, Finland
| | - Oluf Pedersen
- The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jose C. Florez
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
- Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
- Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Andrew P. Morris
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom
- Estonian Genome Centre, University of Tartu, Tartu, Estonia
| | - David Altshuler
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
- Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
- Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America
| | - James B. Meigs
- General Medicine Division, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
| | - Michael Boehnke
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Mark I. McCarthy
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, United Kingdom
| | - Cecilia M. Lindgren
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
- * E-mail: (CML); (ALG)
| | - Anna L. Gloyn
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
- Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, United Kingdom
- * E-mail: (CML); (ALG)
| | | |
Collapse
|
63
|
Go MJ, Hwang JY, Park TJ, Kim YJ, Oh JH, Kim YJ, Han BG, Kim BJ. Genome-wide association study identifies two novel Loci with sex-specific effects for type 2 diabetes mellitus and glycemic traits in a korean population. Diabetes Metab J 2014; 38:375-87. [PMID: 25349825 PMCID: PMC4209352 DOI: 10.4093/dmj.2014.38.5.375] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Accepted: 12/31/2013] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Until recently, genome-wide association study (GWAS)-based findings have provided a substantial genetic contribution to type 2 diabetes mellitus (T2DM) or related glycemic traits. However, identification of allelic heterogeneity and population-specific genetic variants under consideration of potential confounding factors will be very valuable for clinical applicability. To identify novel susceptibility loci for T2DM and glycemic traits, we performed a two-stage genetic association study in a Korean population. METHODS We performed a logistic analysis for T2DM, and the first discovery GWAS was analyzed for 1,042 cases and 2,943 controls recruited from a population-based cohort (KARE, n=8,842). The second stage, de novo replication analysis, was performed in 1,216 cases and 1,352 controls selected from an independent population-based cohort (Health 2, n=8,500). A multiple linear regression analysis for glycemic traits was further performed in a total of 14,232 nondiabetic individuals consisting of 7,696 GWAS and 6,536 replication study participants. A meta-analysis was performed on the combined results using effect size and standard errors estimated for stage 1 and 2, respectively. RESULTS A combined meta-analysis for T2DM identified two new (rs11065756 and rs2074356) loci reaching genome-wide significance in CCDC63 and C12orf51 on the 12q24 region. In addition, these variants were significantly associated with fasting plasma glucose and homeostasis model assessment of β-cell function. Interestingly, two independent single nucleotide polymorphisms were associated with sex-specific stratification in this study. CONCLUSION Our study showed a strong association between T2DM and glycemic traits. We further observed that two novel loci with multiple diverse effects were highly specific to males. Taken together, these findings may provide additional insights into the clinical assessment or subclassification of disease risk in a Korean population.
Collapse
Affiliation(s)
- Min Jin Go
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Joo-Yeon Hwang
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Tae-Joon Park
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Young Jin Kim
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Ji Hee Oh
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Yeon-Jung Kim
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Bok-Ghee Han
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| | - Bong-Jo Kim
- Division of Structural and Functional Genomics, Center for Genome Science, Korea National Institute of Health, Cheongwon, Korea
| |
Collapse
|
64
|
Abstract
That each of us is truly biologically unique, extending to even monozygotic, "identical" twins, is not fully appreciated. Now that it is possible to perform a comprehensive "omic" assessment of an individual, including one's DNA and RNA sequence and at least some characterization of one's proteome, metabolome, microbiome, autoantibodies, and epigenome, it has become abundantly clear that each of us has truly one-of-a-kind biological content. Well beyond the allure of the matchless fingerprint or snowflake concept, these singular, individual data and information set up a remarkable and unprecedented opportunity to improve medical treatment and develop preventive strategies to preserve health.
Collapse
Affiliation(s)
- Eric J Topol
- The Scripps Translational Science Institute, The Scripps Research Institute and Scripps Health, La Jolla, CA 92037, USA.
| |
Collapse
|
65
|
Hang Y, Yamamoto T, Benninger RKP, Brissova M, Guo M, Bush W, Piston DW, Powers AC, Magnuson M, Thurmond DC, Stein R. The MafA transcription factor becomes essential to islet β-cells soon after birth. Diabetes 2014; 63:1994-2005. [PMID: 24520122 PMCID: PMC4030115 DOI: 10.2337/db13-1001] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The large Maf transcription factors, MafA and MafB, are expressed with distinct spatial-temporal patterns in rodent islet cells. Analysis of Mafa(-/-) and pancreas-specific Mafa(∆panc) deletion mutant mice demonstrated a primary role for MafA in adult β-cell activity, different from the embryonic importance of MafB. Our interests here were to precisely define when MafA became functionally significant to β-cells, to determine how this was affected by the brief period of postnatal MafB production, and to identify genes regulated by MafA during this period. We found that islet cell organization, β-cell mass, and β-cell function were influenced by 3 weeks of age in Mafa(Δpanc) mice and compromised earlier in Mafa(Δpanc);Mafb(+/-) mice. A combination of genome-wide microarray profiling, electron microscopy, and metabolic assays were used to reveal mechanisms of MafA control. For example, β-cell replication was produced by actions on cyclin D2 regulation, while effects on granule docking affected first-phase insulin secretion. Moreover, notable differences in the genes regulated by embryonic MafB and postnatal MafA gene expression were found. These results not only clearly define why MafA is an essential transcriptional regulator of islet β-cells, but also why cell maturation involves coordinated actions with MafB.
Collapse
Affiliation(s)
- Yan Hang
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Tsunehiko Yamamoto
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Richard K P Benninger
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Marcela Brissova
- Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | - Min Guo
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Will Bush
- Department of Biomedical Informatics, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, TN
| | - David W Piston
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Alvin C Powers
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TNDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TNVeterans Affairs Tennessee Valley Healthcare System, Nashville, TN
| | - Mark Magnuson
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| | - Debbie C Thurmond
- Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN
| | - Roland Stein
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN
| |
Collapse
|
66
|
de Groot M, Wessel J. Genetic Testing and Type 2 Diabetes Risk Awareness. DIABETES EDUCATOR 2014; 40:427-433. [PMID: 24648440 DOI: 10.1177/0145721714527643] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE The purpose of this study was to examine the motivational, attitudinal, and behavioral predictors of interest in genetic testing (GT) in those with and without awareness of their risk for type 2 diabetes (T2DM). METHODS A convenience sample of adults visiting emergency departments, libraries, or an online research registry was surveyed. Responses from adults without diabetes who reported 1 or more risk factors for T2DM (eg, family history, body mass index > 25) were included in the analyses (n = 265). RESULTS Participants were 37 ± 11 years old, white (54%), and female (69%), with some college education (53%) and an annual income below $25 000 (44%). Approximately half (52%) expressed interest in GT for T2DM. Individuals were stratified by perceived risk for T2DM (risk aware or risk unaware). Among the risk aware, younger age (P < .04) predicted greater interest in GT. Among the risk unaware, family history of T2DM (P < .008) and preference to know genetic risk (P < .0002) predicted interest in GT. Both groups identified the need for low-cost GT. CONCLUSIONS GT is an increasingly available and accurate tool to predict T2DM risk for patients. In this sample, GT was a salient tool for those with and without awareness of their T2DM risk. Financial accessibility is critical to use of this tool for both groups.
Collapse
Affiliation(s)
- Mary de Groot
- School of Medicine, Indiana University, Indianapolis, IN, USA (Dr de Groot, Dr Wessel)
| | - Jennifer Wessel
- School of Medicine, Indiana University, Indianapolis, IN, USA (Dr de Groot, Dr Wessel).,Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA (Dr Wessel)
| |
Collapse
|
67
|
Wang J, Zhang J, Shen J, Hu D, Yan G, Liu X, Xu X, Pei L, Li Y, Sun C. Association of KCNQ1 and KLF14 polymorphisms and risk of type 2 diabetes mellitus: A global meta-analysis. Hum Immunol 2014; 75:342-7. [PMID: 24486580 DOI: 10.1016/j.humimm.2014.01.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Revised: 01/03/2014] [Accepted: 01/14/2014] [Indexed: 12/31/2022]
Abstract
rs151290 in KCNQ1 and rs972283 in KLF14 have been evaluated in terms of risk of type 2 diabetes mellitus (T2DM), but the results are inconsistent. We performed an meta-analysis to assess the contributions of rs151290 in KCNQ1 and rs972283 in KLF14 to risk of T2DM. We searched the worldwide literature published from 2008 to 2013 in MEDLINE via PubMed, EMBASE, Cochrane CENTRAL and Chinese databases. Two reviewers extracted data independently using a standardized protocol, and any discrepancies were resolved by a third reviewer. Fixed- and random-effects meta-analyses were performed to pool the odds ratios (ORs). Publication bias and heterogeneity were examined. A total of 11 articles were included in the meta-analysis: 6 studies with 6696 cases and 7151 controls investigated rs151290 in KCNQ1, and 5 studies with 50,552 cases and 106,535 controls investigated rs972283 in KLF14. We obtained highly significant ORs for the risk allele C for rs151290 and the risk allele G for rs972283. The population attributable risk percentage for rs151290 and rs972283 was 6.83% and 4.18%, respectively. The risk allele C of rs151290 in KCNQ1 and risk allele G of rs972283 in KLF14 were both associated with increased risk of T2DM in a global population.
Collapse
Affiliation(s)
- Jinjin Wang
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Jianfeng Zhang
- Henan Armed Police Corps Hospital, Zhengzhou 450000, People's Republic of China.
| | - Jie Shen
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Dongsheng Hu
- Shenzhen University School of Medicine, Shenzhen 518060, People's Republic of China.
| | - Guoli Yan
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Xiaohui Liu
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Xueqin Xu
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Lanying Pei
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Yanfang Li
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| | - Chunyang Sun
- Discipline of Public Health and Preventive Medicine, Center of Preventive Medicine Research and Assessment, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, People's Republic of China.
| |
Collapse
|
68
|
Marullo L, El-Sayed Moustafa JS, Prokopenko I. Insights into the genetic susceptibility to type 2 diabetes from genome-wide association studies of glycaemic traits. Curr Diab Rep 2014; 14:551. [PMID: 25344220 DOI: 10.1007/s11892-014-0551-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Over the past 8 years, the genetics of complex traits have benefited from an unprecedented advancement in the identification of common variant loci for diseases such as type 2 diabetes (T2D). The ability to undertake genome-wide association studies in large population-based samples for quantitative glycaemic traits has permitted us to explore the hypothesis that models arising from studies in non-diabetic individuals may reflect mechanisms involved in the pathogenesis of diabetes. Amongst 88 T2D risk and 72 glycaemic trait loci, only 29 are shared and show disproportionate magnitudes of phenotypic effects. Important mechanistic insights have been gained regarding the physiological role of T2D loci in disease predisposition through the elucidation of their contribution to glycaemic trait variability. Further investigation is warranted to define causal variants within these loci, including functional characterisation of associated variants, to dissect their role in disease mechanisms and to enable clinical translation.
Collapse
Affiliation(s)
- Letizia Marullo
- Department of Life Sciences and Biotechnology, Genetic Section, University of Ferrara, Via L. Borsari 46, 44121, Ferrara, Italy
| | | | | |
Collapse
|
69
|
Bouatia-Naji N. Nouveaux déterminants génétiques des traits glycémiques. Med Sci (Paris) 2014; 30:27-9. [DOI: 10.1051/medsci/20143001008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
70
|
O'Brien RM. Moving on from GWAS: functional studies on the G6PC2 gene implicated in the regulation of fasting blood glucose. Curr Diab Rep 2013; 13:768-77. [PMID: 24142592 PMCID: PMC4041587 DOI: 10.1007/s11892-013-0422-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Genome-wide association studies (GWAS) have shown that single-nucleotide polymorphisms (SNPs) in G6PC2 are the most important common determinants of variations in fasting blood glucose (FBG) levels. Molecular studies examining the functional impact of these SNPs on G6PC2 gene transcription and splicing suggest that they affect FBG by directly modulating G6PC2 expression. This conclusion is supported by studies on G6pc2 knockout (KO) mice showing that G6pc2 represents a negative regulator of basal glucose-stimulated insulin secretion that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux and opposing the action of glucokinase. Suppression of G6PC2 activity might, therefore, represent a novel therapy for lowering FBG and the risk of cardiovascular-associated mortality. GWAS and G6pc2 KO mouse studies also suggest that G6PC2 affects other aspects of beta cell function. The evolutionary benefit conferred by G6PC2 remains unclear, but it is unlikely to be related to its ability to modulate FBG.
Collapse
Affiliation(s)
- Richard M O'Brien
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA,
| |
Collapse
|
71
|
McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Erar B, Kahn SE, Knowler WC, Lipkin EW, Kitabchi AE, Wagenknecht LE, Wing RR. Human cardiovascular disease IBC chip-wide association with weight loss and weight regain in the look AHEAD trial. Hum Hered 2013; 75:160-74. [PMID: 24081232 PMCID: PMC4257841 DOI: 10.1159/000353181] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND/AIMS The present study identified genetic predictors of weight change during behavioral weight loss treatment. METHODS Participants were 3,899 overweight/obese individuals with type 2 diabetes from Look AHEAD, a randomized controlled trial to determine the effects of intensive lifestyle intervention (ILI), including weight loss and physical activity, relative to diabetes support and education, on cardiovascular outcomes. Analyses focused on associations of single nucleotide polymorphisms (SNPs) on the Illumina CARe iSelect (IBC) chip (minor allele frequency >5%; n = 31,959) with weight change at year 1 and year 4, and weight regain at year 4, among individuals who lost ≥ 3% at year 1. RESULTS Two novel regions of significant chip-wide association with year-1 weight loss in ILI were identified (p < 2.96E-06). ABCB11 rs484066 was associated with 1.16 kg higher weight per minor allele at year 1, whereas TNFRSF11A, or RANK, rs17069904 was associated with 1.70 kg lower weight per allele at year 1. CONCLUSIONS This study, the largest to date on genetic predictors of weight loss and regain, indicates that SNPs within ABCB11, related to bile salt transfer, and TNFRSF11A, implicated in adipose tissue physiology, predict the magnitude of weight loss during behavioral intervention. These results provide new insights into potential biological mechanisms and may ultimately inform weight loss treatment.
Collapse
Affiliation(s)
- Jeanne M McCaffery
- Weight Control and Diabetes Research Center, Department of Psychiatry and Human Behavior, The Miriam Hospital and Brown Medical School, Providence, R.I., USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Fesinmeyer MD, Meigs JB, North KE, Schumacher FR, Bůžková P, Franceschini N, Haessler J, Goodloe R, Spencer KL, Voruganti VS, Howard BV, Jackson R, Kolonel LN, Liu S, Manson JE, Monroe KR, Mukamal K, Dilks HH, Pendergrass SA, Nato A, Wan P, Wilkens LR, Le Marchand L, Ambite JL, Buyske S, Florez JC, Crawford DC, Hindorff LA, Haiman CA, Peters U, Pankow JS. Genetic variants associated with fasting glucose and insulin concentrations in an ethnically diverse population: results from the Population Architecture using Genomics and Epidemiology (PAGE) study. BMC MEDICAL GENETICS 2013; 14:98. [PMID: 24063630 PMCID: PMC3849560 DOI: 10.1186/1471-2350-14-98] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Accepted: 09/10/2013] [Indexed: 11/10/2022]
Abstract
BACKGROUND Multiple genome-wide association studies (GWAS) within European populations have implicated common genetic variants associated with insulin and glucose concentrations. In contrast, few studies have been conducted within minority groups, which carry the highest burden of impaired glucose homeostasis and type 2 diabetes in the U.S. METHODS As part of the 'Population Architecture using Genomics and Epidemiology (PAGE) Consortium, we investigated the association of up to 10 GWAS-identified single nucleotide polymorphisms (SNPs) in 8 genetic regions with glucose or insulin concentrations in up to 36,579 non-diabetic subjects including 23,323 European Americans (EA) and 7,526 African Americans (AA), 3,140 Hispanics, 1,779 American Indians (AI), and 811 Asians. We estimated the association between each SNP and fasting glucose or log-transformed fasting insulin, followed by meta-analysis to combine results across PAGE sites. RESULTS Overall, our results show that 9/9 GWAS SNPs are associated with glucose in EA (p = 0.04 to 9 × 10-15), versus 3/9 in AA (p= 0.03 to 6 × 10-5), 3/4 SNPs in Hispanics, 2/4 SNPs in AI, and 1/2 SNPs in Asians. For insulin we observed a significant association with rs780094/GCKR in EA, Hispanics and AI only. CONCLUSIONS Generalization of results across multiple racial/ethnic groups helps confirm the relevance of some of these loci for glucose and insulin metabolism. Lack of association in non-EA groups may be due to insufficient power, or to unique patterns of linkage disequilibrium.
Collapse
Affiliation(s)
- Megan D Fesinmeyer
- Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis MN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Abstract
The pancreatic islet β cell senses circulating levels of calorigenic nutrients to secrete insulin according to the needs of the organism. Altered insulin secretion is linked to various disorders such as diabetes, hypoglycemic states, and cardiometabolic diseases. Fuel stimuli, including glucose, free fatty acids, and amino acids, promote insulin granule exocytosis primarily via their metabolism in β cells and the production of key signaling metabolites. This paper reviews our current knowledge of the pathways involved in both positive and negative metabolic signaling for insulin secretion and assesses the role of established and candidate metabolic coupling factors, keeping recent developments in focus.
Collapse
Affiliation(s)
- Marc Prentki
- Molecular Nutrition Unit, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, QC, Canada.
| | | | | |
Collapse
|
74
|
Large scale meta-analyses of fasting plasma glucose raising variants in GCK, GCKR, MTNR1B and G6PC2 and their impacts on type 2 diabetes mellitus risk. PLoS One 2013; 8:e67665. [PMID: 23840762 PMCID: PMC3695948 DOI: 10.1371/journal.pone.0067665] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2013] [Accepted: 05/22/2013] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The evidence that the variants GCK rs1799884, GCKR rs780094, MTNR1B rs10830963 and G6PC2 rs560887, which are related to fasting plasma glucose levels, increase the risk of type 2 diabetes mellitus (T2DM) is contradictory. We therefore performed a meta-analysis to derive a more precise estimation of the association between these polymorphisms and T2DM. METHODS All the publications examining the associations of these variants with risk of T2DM were retrieved from the MEDLINE and EMBASE databases. Using the data from the retrieved articles, we computed summary estimates of the associations of the four variants with T2DM risk. We also examined the studies for heterogeneity, as well as for bias of the publications. RESULTS A total of 113,025 T2DM patients and 199,997 controls from 38 articles were included in the meta-analysis. Overall, the pooled results indicated that GCK (rs1799884), GCKR (rs780094) and MTNR1B (rs10830963) were significantly associated with T2DM susceptibility (OR, 1.04; 95%CI, 1.01-1.08; OR, 1.08; 95%CI, 1.05-1.12 and OR, 1.05; 95%CI, 1.02-1.08, respectively). After stratification by ethnicity, significant associations for the GCK, MTNR1B and G6PC2 variants were detected only in Caucasians (OR, 1.09; 95%CI, 1.02-1.16; OR, 1.10; 95%CI, 1.08-1.13 and OR, 0.97; 95%CI, 0.95-0.99, respectively), but not in Asians (OR, 1.02, 95% CI 0.98-1.05; OR, 1.01; 95%CI, 0.98-1.04 and OR, 1.12; 95%CI, 0.91-1.32, respectively). CONCLUSIONS Our meta-analyses demonstrated that GCKR rs780094 variant confers high cross-ethnicity risk for the development of T2DM, while significant associations between GCK, MTNR1B and G6PC2 variants and T2DM risk are limited to Caucasians.
Collapse
|
75
|
Yang T, Hohenstein AC, Lee CE, Hutton JC, Davidson HW. Mapping I-A(g7) restricted epitopes in murine G6PC2. Immunol Res 2013; 55:91-9. [PMID: 22983906 DOI: 10.1007/s12026-012-8368-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
G6PC2, also known as islet-specific glucose 6-phosphatase catalytic subunit-related protein (IGRP), is a major target of autoreactive CD8(+) T cells in both diabetic human subjects and the non-obese diabetic (NOD) mouse. However, in contrast to the abundant literature regarding the CD8(+) response to this antigen, much less is known about the potential involvement of IGRP-reactive CD4(+) T cells in diabetogenesis. The single previous study that examined this question in NOD mice was based upon a candidate epitope approach and identified three I-A(g7)-restricted epitopes that each elicited spontaneous responses in these animals. However, given the known inaccuracies of MHC class II epitope prediction algorithms, we hypothesized that additional specificities might also be targeted. To address this issue, we immunized NOD mice with membranes from insect cells overexpressing full-length recombinant mouse IGRP and measured recall responses of purified CD4(+) T cells using a library of overlapping peptides encompassing the entire 355-aa primary sequence. Nine peptides representing 8 epitopes gave recall responses, only 1 of which corresponded to any of the previously reported sequences. In each case proliferation was blocked by a monoclonal antibody to I-A(g7), but not the appropriate isotype control. Consistent with a role in diabetogenesis, proliferative responses to 4 of the 9 peptides (3 epitopes) were also detected in CD4(+) T cells purified from the pancreatic draining lymph nodes of pre-diabetic female animals, but not from peripheral lymph nodes or spleens of the same animals. Intriguingly, one of the newly identified spontaneously reactive epitopes (P8 [IGRP(55-72)]) is highly conserved between mice and man, suggesting that it might also be a target of HLA-DQ8-restricted T cells in diabetic human subjects, an hypothesis that we are currently testing.
Collapse
Affiliation(s)
- Tao Yang
- Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | | | | | | | | |
Collapse
|
76
|
Sanda S, Wei S, Rue T, Shilling H, Greenbaum C. A SNP in G6PC2 predicts insulin secretion in type 1 diabetes. Acta Diabetol 2013; 50:459-62. [PMID: 22438186 DOI: 10.1007/s00592-012-0389-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2012] [Accepted: 03/06/2012] [Indexed: 01/28/2023]
Abstract
We investigated whether single nucleotide polymorphisms in genes related to glucose metabolism correlate with insulin secretion in type 1 diabetes patients. A cohort of 49 type 1 diabetes patients underwent serial mixed meal tolerance tests to assess insulin secretion. Patients were genotyped for SNPs related to glucose metabolism: CDKAL1 rs7754840, G6PC2 rs560887, HHEX rs1111875, KCNJ11 rs5215. Recently diagnosed patients (<100 days) homozygous for the G allele of G6PC2 had higher area under the curve C-peptide on mixed meal tolerance tests compared to non-homozygous patients (344.8 ± 203.2 vs. 167.9 ± 131.5, p = 0.04). Other SNPs did not correlate with insulin secretion in the new onset period. In a longitudinal survival analysis, homozygosity for the minor allele (A) in G6PC2 predicted more rapid loss of insulin secretion over time. A SNP in the beta cell gene G6PC2 may correlate with preserved insulin secretion in type 1 diabetes.
Collapse
Affiliation(s)
- Srinath Sanda
- Benaroya Research Institute, 1201 9th Ave., IN-RC, Seattle, WA 98101, USA.
| | | | | | | | | |
Collapse
|
77
|
Baerenwald DA, Bonnefond A, Bouatia-Naji N, Flemming BP, Umunakwe OC, Oeser JK, Pound LD, Conley NL, Cauchi S, Lobbens S, Eury E, Balkau B, Lantieri O, Dadi PK, Jacobson DA, Froguel P, O’Brien RM. Multiple functional polymorphisms in the G6PC2 gene contribute to the association with higher fasting plasma glucose levels. Diabetologia 2013; 56:1306-16. [PMID: 23508304 PMCID: PMC4106008 DOI: 10.1007/s00125-013-2875-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Accepted: 01/28/2013] [Indexed: 01/14/2023]
Abstract
AIMS/HYPOTHESIS We previously identified the G6PC2 locus as a strong determinant of fasting plasma glucose (FPG) and showed that a common G6PC2 intronic single nucleotide polymorphism (SNP) (rs560887) and two common G6PC2 promoter SNPs (rs573225 and rs13431652) are highly associated with FPG. However, these promoter SNPs have complex effects on G6PC2 fusion gene expression, and our data suggested that only rs13431652 is a potentially causative SNP. Here we examine the effect of rs560887 on G6PC2 pre-mRNA splicing and the contribution of an additional common G6PC2 promoter SNP, rs2232316, to the association signal. METHODS Minigene analyses were used to characterise the effect of rs560887 on G6PC2 pre-mRNA splicing. Fusion gene and gel retardation analyses characterised the effect of rs2232316 on G6PC2 promoter activity and transcription factor binding. The genetic association of rs2232316 with FPG variation was assessed using regression adjusted for age, sex and BMI in 4,220 Europeans with normal FPG. RESULTS The rs560887-G allele was shown to enhance G6PC2 pre-mRNA splicing, whereas the rs2232316-A allele enhanced G6PC2 transcription by promoting Foxa2 binding. Genetic analyses provide evidence for association of the rs2232316-A allele with increased FPG (β = 0.04 mmol/l; p = 4.3 × 10(-3)) as part of the same signal as rs560887, rs573225 and rs13431652. CONCLUSIONS/INTERPRETATION As with rs13431652, the in situ functional data with rs560887 and rs2232316 are in accord with the putative function of G6PC2 in pancreatic islets, and suggest that all three are potentially causative SNPs that contribute to the association between G6PC2 and FPG.
Collapse
Affiliation(s)
- D. A. Baerenwald
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - A. Bonnefond
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
| | - N. Bouatia-Naji
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
- INSERM U970, Paris Cardiovascular Research Center PARCC, 56 rue Leblanc, F-75015 Paris, France
| | - B. P. Flemming
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - O. C. Umunakwe
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - J. K. Oeser
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - L. D. Pound
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - N. L. Conley
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - S. Cauchi
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
| | - S. Lobbens
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
| | - E. Eury
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
| | - B. Balkau
- INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Epidemiology of diabetes, obesity and chronic renal disease over the lifecourse, F-94807, Villejuif, France
- Université Paris-Sud 11, UMRS 1018, F-94807 Villejuif, France
| | - O. Lantieri
- Institut inter-régional pour la santé (IRSA), F-37521 La Riche, France
| | - MAGIC Investigators
- Meta-Analysis of Glucose and Insulin related traits Consortium Investigators (http://www.magicinvestigators.org/)
| | - P. K. Dadi
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - D. A. Jacobson
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| | - P. Froguel
- CNRS-UMR-8199, Institut Pasteur de Lille, F-59019, Lille, France
- University Lille Nord de France, F-59019 Lille, France
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, W12 0NN London, UK
| | - R. M. O’Brien
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 37232 Nashville, Tennessee, USA
| |
Collapse
|
78
|
Pound LD, Oeser JK, O’Brien TP, Wang Y, Faulman CJ, Dadi PK, Jacobson DA, Hutton JC, McGuinness OP, Shiota M, O’Brien RM. G6PC2: a negative regulator of basal glucose-stimulated insulin secretion. Diabetes 2013; 62:1547-56. [PMID: 23274894 PMCID: PMC3636628 DOI: 10.2337/db12-1067] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Elevated fasting blood glucose (FBG) is associated with increased risk for the development of type 2 diabetes and cardiovascular-associated mortality. Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not insulin sensitivity or glucose tolerance. G6PC2 encodes an islet-specific, endoplasmic reticulum-resident glucose-6-phosphatase catalytic subunit. A combination of in situ perfused pancreas, in vitro isolated islet, and in vivo analyses were used to explore the function of G6pc2 in mice. G6pc2 deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data. G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS). As a consequence, under fasting conditions in which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data. Glucose-6-phosphatase activity was reduced, whereas basal cytoplasmic calcium levels were elevated in islets isolated from G6pc2 KO mice. These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux.
Collapse
Affiliation(s)
- Lynley D. Pound
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - James K. Oeser
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Tracy P. O’Brien
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Yingda Wang
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Chandler J. Faulman
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Prasanna K. Dadi
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - David A. Jacobson
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - John C. Hutton
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, Colorado
| | - Owen P. McGuinness
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Masakazu Shiota
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
| | - Richard M. O’Brien
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, Tennessee
- Corresponding author: Richard M. O’Brien,
| |
Collapse
|
79
|
Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BHR, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the Lifelines Cohort Study. J Intern Med 2013; 273:283-93. [PMID: 23121487 DOI: 10.1111/joim.12010] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVES Glycated haemoglobin (HbA1c) is associated with cardiovascular disease risk in individuals without diabetes, and its use has been recommended for diagnosing diabetes. Therefore, it is important to gain further understanding of the determinants of HbA1c. The aim of this study was to investigate the effects of genetic loci and clinical and lifestyle parameters, and their interactions, on HbA1c in nondiabetic adults. DESIGN Population-based cohort study. SETTING Three northern provinces of the Netherlands. SUBJECTS A total of 2921 nondiabetic adults participating in the population-based LifeLines Cohort Study. MEASUREMENTS Body mass index (BMI), waist circumference, HbA1c, fasting plasma glucose (FPG) and erythrocyte indices were measured. Data on current smoking and alcohol consumption were collected through questionnaires. Genome-wide genotyping was performed, and 12 previously identified single-nucleotide polymorphisms (SNPs) were selected for replication and categorized as 'glycaemic' and 'nonglycaemic' SNPs according to their presumed mechanism(s) of action on HbA1c. Genetic risk scores (GRSs) were calculated as the sum of the weighted effect of HbA1c-increasing alleles. RESULTS Age, gender, BMI, FPG, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, current smoking and alcohol consumption were independent predictors of HbA1c, together explaining 26.2% of the variance in HbA1c, with FPG contributing 10.9%. We replicated three of the previously identified SNPs and the GRSs were also found to be independently associated with HbA1c. We found a smaller effect of the 'nonglycaemic GRS' in females compared with males and an attenuation of the effect of the GRS of all 12 SNPs with increasing BMI. CONCLUSIONS Our results suggest that a substantial portion of HbA1c is determined by nonglycaemic factors. This should be taken into account when considering the use of HbA1c as a diagnostic test for diabetes.
Collapse
Affiliation(s)
- H Jansen
- Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
| | | | | | | | | | | |
Collapse
|
80
|
Boonpeng H, Yusoff K. The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges. Mol Cytogenet 2013; 6:8. [PMID: 23448375 PMCID: PMC3599593 DOI: 10.1186/1755-8166-6-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Accepted: 01/03/2013] [Indexed: 01/08/2023] Open
Abstract
The ultimate goal of human genetics is to understand the role of genome variation in elucidating human traits and diseases. Besides single nucleotide polymorphism (SNP), copy number variation (CNV), defined as gains or losses of a DNA segment larger than 1 kb, has recently emerged as an important tool in understanding heritable source of human genomic differences. It has been shown to contribute to genetic susceptibility of various common and complex diseases. Despite a handful of publications, its role in cardiovascular diseases remains largely unknown. Here, we deliberate on the currently available technologies for CNV detection. The possible utility and the potential roles of CNV in exploring the mechanisms of cardiac remodeling in hypertension will also be addressed. Finally, we discuss the challenges for investigations of CNV in cardiovascular diseases and its possible implications in diagnosis of hypertension-related left ventricular hypertrophy (LVH).
Collapse
Affiliation(s)
- Hoh Boonpeng
- Institute of Medical Molecular Biotechnology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai, Buloh, 47000, Malaysia.
| | | |
Collapse
|
81
|
Multiple roles of glucose-6-phosphatases in pathophysiology. Biochim Biophys Acta Gen Subj 2013; 1830:2608-18. [DOI: 10.1016/j.bbagen.2012.12.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2012] [Revised: 12/11/2012] [Accepted: 12/13/2012] [Indexed: 12/28/2022]
|
82
|
Boztug K, Klein C. Genetics and Pathophysiology of Severe Congenital Neutropenia Syndromes Unrelated to Neutrophil Elastase. Hematol Oncol Clin North Am 2013; 27:43-60, vii. [DOI: 10.1016/j.hoc.2012.11.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
83
|
Xia Q, Chen ZX, Wang YC, Ma YS, Zhang F, Che W, Fu D, Wang XF. Association between the melatonin receptor 1B gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PLoS One 2012; 7:e50107. [PMID: 23226241 PMCID: PMC3511448 DOI: 10.1371/journal.pone.0050107] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 10/19/2012] [Indexed: 01/11/2023] Open
Abstract
Background Melatonin receptor 1B (MTNR1B) belongs to the seven-transmembrane G protein-coupled receptor superfamily involved in insulin secretion, which has attracted considerable attention as a candidate gene for type 2 diabetes (T2D) since it was first identified as a loci associated with fasting plasma glucose level through genome wide association approach. The relationship between MTNR1B and T2D has been reported in various ethnic groups. The aim of this study was to consolidate and summarize published data on the potential of MTNR1B polymorphisms in T2D risk prediction. Methods PubMed, EMBASE, ISI web of science and the CNKI databases were systematically searched to identify relevant studies. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Heterogeneity and publication bias were also tested. Results A total of 23 studies involving 172,963 subjects for two common polymorphisms (rs10830963, rs1387153) on MTNR1B were included. An overall random effects per-allele OR of 1.05 (95% CI: 1.02–1.08; P<10−4) and 1.04 (95% CI: 0.98–1.10; P = 0.20) were found for the two variants respectively. Similar results were also observed using dominant or recessive genetic model. There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. Significant results were found in Caucasians when stratified by ethnicity; while no significant associations were observed in East Asians and South Asians. Besides, we found that the rs10830963 polymorphism is a risk factor associated with increased impaired glucose regulation susceptibility. Conclusions This meta-analysis demonstrated that the rs10830963 polymorphism is a risk factor for developing impaired glucose regulation and T2D.
Collapse
MESH Headings
- Alleles
- Asian People
- Databases, Bibliographic
- Diabetes Mellitus, Type 2/ethnology
- Diabetes Mellitus, Type 2/genetics
- Diabetes Mellitus, Type 2/metabolism
- Female
- Genome-Wide Association Study
- Genotype
- Glucose/metabolism
- Humans
- Insulin/metabolism
- Male
- Models, Genetic
- Polymorphism, Genetic
- Receptor, Melatonin, MT1/genetics
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT2
- Risk
- White People
Collapse
Affiliation(s)
- Qing Xia
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Zi-Xian Chen
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Yi-Chao Wang
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Yu-Shui Ma
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Feng Zhang
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Wu Che
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Da Fu
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
- * E-mail: (DF); (XFW)
| | - Xiao-Feng Wang
- Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
- * E-mail: (DF); (XFW)
| |
Collapse
|
84
|
Liu DJ, Leal SM. A unified method for detecting secondary trait associations with rare variants: application to sequence data. PLoS Genet 2012; 8:e1003075. [PMID: 23166519 PMCID: PMC3499373 DOI: 10.1371/journal.pgen.1003075] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 09/23/2012] [Indexed: 01/11/2023] Open
Abstract
Next-generation sequencing has made possible the detection of rare variant (RV) associations with quantitative traits (QT). Due to high sequencing cost, many studies can only sequence a modest number of selected samples with extreme QT. Therefore association testing in individual studies can be underpowered. Besides the primary trait, many clinically important secondary traits are often measured. It is highly beneficial if multiple studies can be jointly analyzed for detecting associations with commonly measured traits. However, analyzing secondary traits in selected samples can be biased if sample ascertainment is not properly modeled. Some methods exist for analyzing secondary traits in selected samples, where some burden tests can be implemented. However p-values can only be evaluated analytically via asymptotic approximations, which may not be accurate. Additionally, potentially more powerful sequence kernel association tests, variable selection-based methods, and burden tests that require permutations cannot be incorporated. To overcome these limitations, we developed a unified method for analyzing secondary trait associations with RVs (STAR) in selected samples, incorporating all RV tests. Statistical significance can be evaluated either through permutations or analytically. STAR makes it possible to apply more powerful RV tests to analyze secondary trait associations. It also enables jointly analyzing multiple cohorts ascertained under different study designs, which greatly boosts power. The performance of STAR and commonly used RV association tests were comprehensively evaluated using simulation studies. STAR was also implemented to analyze a dataset from the SardiNIA project where samples with extreme low-density lipoprotein levels were sequenced. A significant association between LDLR and systolic blood pressure was identified, which is supported by pharmacogenetic studies. In summary, for sequencing studies, STAR is an important tool for detecting secondary-trait RV associations. Next-generation sequencing has greatly expanded our ability to identify missing heritability due to rare variants. In order to increase the power to detect associations, one desirable study design is to combine samples from multiple cohorts for mapping commonly measured traits. However, many current studies sequence selected samples (e.g. samples with extreme QT), which can bias the analysis of secondary traits, unless the sampling ascertainment mechanisms are properly adjusted. We developed a unified method for detecting secondary trait associations with rare variants (STAR) in selected and random samples, which can flexibly incorporate all rare variant association tests and allow joint analysis of multiple cohorts ascertained under different study designs. We demonstrate via simulations that STAR greatly boosts the power for detecting secondary trait associations. As an application of STAR, a dataset from the SardiNIA project was analyzed, where DNA samples from well-phenotyped individuals with extreme low-density lipoprotein levels were sequenced. LDLR was identified to be significantly associated with systolic blood pressure, which is supported by a previous pharmacogenetics study. In conclusion, STAR is an important tool for sequence-based association studies.
Collapse
Affiliation(s)
- Dajiang J. Liu
- Department of Biostatistics, Center of Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
- * E-mail: (DJL); (SML)
| | - Suzanne M. Leal
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America
- * E-mail: (DJL); (SML)
| |
Collapse
|
85
|
Borowiec M, Fendler W, Dusatkova P, Antosik K, Pruhova S, Cinek O, Mysliwiec M, Jarosz-Chobot P, Malecki MT, Mlynarski W. HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2). Diabet Med 2012; 29:1465-9. [PMID: 22486180 DOI: 10.1111/j.1464-5491.2012.03671.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIMS Genetic variation at the rs560887 locus of the glucose-6-phosphatase, catalytic 2 gene (G6PC2) is known to affect regulation of fasting glycaemia. We determined the rs560887 genotype of patients with monogenic diabetes and glucokinase gene mutations (GCK-MODY) and correlated the genotypes with HbA(1c) levels. METHODS Patients from families with GCK-MODY were recruited from two large cohorts from Poland (n = 128) and the Czech Republic (n = 154). Genotypes at the rs560887 polymorphic site in G6PC2 were examined using real-time quantitative polymerase chain reaction. The effect of rs560887 genotype on age at diagnosis of GCK-MODY and initial HbA(1c) levels were evaluated separately within both cohorts. Following that, a meta-analysis of rs560887 genotype-HbA(1c) associations of both Polish and Czech cohorts was performed to confirm homogeneity of findings and validate cohort-specific results. RESULTS GG homozygosity at rs560887 was associated with marginally elevated HbA(1c) levels (P = 0.07 in both cohorts). The effects observed in both groups were very homogeneous (Q = 0.18; P = 0.68). Meta-analysis showed that GG homozygosity at rs560887 was associated with mean HbA(1c) levels higher by 2.4 mmol/mol (0.24%), 95% CI 0.5-4.4 mmol/mol (0.05-0.44%) than in individuals with other genotypes. Additionally, meta-analysis of both cohorts showed that GG homozygous individuals had higher odds of reaching the 48 mmol/mol (6.5%) diagnostic threshold of diabetes; (odds ratio 1.90; 95% CI 1.07-3.36; P = 0.03). No such effects were observed for age at diagnosis of diabetes. CONCLUSIONS Variation at the rs560887 locus of G6PC2 is associated with worse glycated haemoglobin levels in individuals with GCK mutations; GG homozygotes are more likely to meet diagnostic criteria for diabetes based on HbA(1c) level.
Collapse
Affiliation(s)
- M Borowiec
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, Poland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Been LF, Hatfield JL, Shankar A, Aston CE, Ralhan S, Wander GS, Mehra NK, Singh JR, Mulvihill JJ, Sanghera DK. A low frequency variant within the GWAS locus of MTNR1B affects fasting glucose concentrations: genetic risk is modulated by obesity. Nutr Metab Cardiovasc Dis 2012; 22:944-951. [PMID: 21558052 PMCID: PMC3155734 DOI: 10.1016/j.numecd.2011.01.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2010] [Revised: 11/24/2010] [Accepted: 01/03/2011] [Indexed: 12/14/2022]
Abstract
Two common variants (rs1387153, rs10830963) in MTNR1B have been reported to have independent effects on fasting blood glucose (FBG) levels with increased risk to type 2 diabetes (T2D) in recent genome-wide association studies (GWAS). In this investigation, we report the association of these two variants, and an additional variant (rs1374645) within the GWAS locus of MTNR1B with FBG, 2h glucose, insulin resistance (HOMA IR), β-cell function (HOMA B), and T2D in our sample of Asian Sikhs from India. Our cohort comprised 2222 subjects [1201 T2D, 1021 controls]. None of these SNPs was associated with T2D in this cohort. Our data also could not confirm association of rs1387153 and rs10830963 with FBG phenotype. However, upon stratifying data according to body mass index (BMI) (low ≤ 25 kg/m(2) and high > 25 kg/m(2)) in normoglycemic subjects (n = 1021), the rs1374645 revealed a strong association with low FBG levels in low BMI group (β = -0.073, p = 0.002, Bonferroni p = 0.01) compared to the high BMI group (β = 0.015, p = 0.50). We also detected a strong evidence of interaction between rs1374645 and BMI with respect to FBG levels (p = 0.002). Our data provide new information about the significant impact of another MTNR1B variant on FBG levels that appears to be modulated by BMI. Future confirmation on independent datasets and functional studies will be required to define the role of this variant in fasting glucose variation.
Collapse
Affiliation(s)
- L. F. Been
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - J. L. Hatfield
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - A. Shankar
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - C. E. Aston
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- General Clinical Research Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - S. Ralhan
- Hero DMC Heart Institute, Ludhiana, Punjab, India
| | - G. S. Wander
- Hero DMC Heart Institute, Ludhiana, Punjab, India
| | - N. K. Mehra
- All India Institute of Medical Sciences, New Delhi, India
| | - J. R. Singh
- Central University of Punjab, Bathinda, Punjab, India
| | - J. J. Mulvihill
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - D. K. Sanghera
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| |
Collapse
|
87
|
Bonilla C, Lawlor DA, Ben-Shlomo Y, Ness AR, Gunnell D, Ring SM, Smith GD, Lewis SJ. Maternal and offspring fasting glucose and type 2 diabetes-associated genetic variants and cognitive function at age 8: a Mendelian randomization study in the Avon Longitudinal Study of Parents and Children. BMC MEDICAL GENETICS 2012; 13:90. [PMID: 23013243 PMCID: PMC3570299 DOI: 10.1186/1471-2350-13-90] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2012] [Accepted: 09/20/2012] [Indexed: 01/30/2023]
Abstract
Background In observational epidemiological studies type 2 diabetes (T2D) and both low and high plasma concentrations of fasting glucose have been found to be associated with lower cognitive performance. These associations could be explained by confounding. Methods In this study we looked at the association between genetic variants, known to be robustly associated with fasting glucose and T2D risk, in the mother and her offspring to determine whether there is likely to be a causal link between early life exposure to glucose and child’s intelligence quotient (IQ) scores in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. We generated a fasting glucose (FGGRS) and a T2D (T2DGRS) genetic risk score and used them in a Mendelian randomization approach. Results We found a strong correlation between the FGGRS and fasting glucose plasma measurements that were available for a subset of children, but no association of either the maternal or the offspring FGGRS with child’s IQ was observed. In contrast, the maternal T2DGRS was positively associated with offspring IQ. Conclusions Maternal and offspring genetic variants which are associated with glucose levels are not associated with offspring IQ, suggesting that there is unlikely to be a causal link between glucose exposure in utero and IQ in childhood. Further exploration in even larger cohorts is required to exclude the possibility that our null findings were due to a lack of statistical power.
Collapse
Affiliation(s)
- Carolina Bonilla
- School of Social and Community Medicine, University of Bristol, Bristol, UK.
| | | | | | | | | | | | | | | |
Collapse
|
88
|
Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One 2012; 7:e44424. [PMID: 22984506 PMCID: PMC3439414 DOI: 10.1371/journal.pone.0044424] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Accepted: 08/03/2012] [Indexed: 11/19/2022] Open
Abstract
Common genetic variants have been recently associated with fasting glucose and insulin levels in white populations. Whether these associations replicate in pre-diabetes is not known. We extended these findings to the Diabetes Prevention Program, a clinical trial in which participants at high risk for diabetes were randomized to placebo, lifestyle modification or metformin for diabetes prevention. We genotyped previously reported polymorphisms (or their proxies) in/near G6PC2, MTNR1B, GCK, DGKB, GCKR, ADCY5, MADD, CRY2, ADRA2A, FADS1, PROX1, SLC2A2, GLIS3, C2CD4B, IGF1, and IRS1 in 3,548 Diabetes Prevention Program participants. We analyzed variants for association with baseline glycemic traits, incident diabetes and their interaction with response to metformin or lifestyle intervention. We replicated associations with fasting glucose at MTNR1B (P<0.001), G6PC2 (P = 0.002) and GCKR (P = 0.001). We noted impaired β-cell function in carriers of glucose-raising alleles at MTNR1B (P<0.001), and an increase in the insulinogenic index for the glucose-raising allele at G6PC2 (P<0.001). The association of MTNR1B with fasting glucose and impaired β-cell function persisted at 1 year despite adjustment for the baseline trait, indicating a sustained deleterious effect at this locus. We also replicated the association of MADD with fasting proinsulin levels (P<0.001). We detected no significant impact of these variants on diabetes incidence or interaction with preventive interventions. The association of several polymorphisms with quantitative glycemic traits is replicated in a cohort of high-risk persons. These variants do not have a detectable impact on diabetes incidence or response to metformin or lifestyle modification in the Diabetes Prevention Program.
Collapse
Affiliation(s)
- Jose C. Florez
- Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
- * E-mail: (DPPRG); (JCF)
| | - Kathleen A. Jablonski
- The Biostatistics Center, George Washington University, Rockville, Maryland, United States of America
| | - Jarred B. McAteer
- Center for Human Genetic Research and Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Paul W. Franks
- Lund University Diabetes Center, Department of Clinical Sciences, Lund University, Malmö, Sweden
- Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America
| | - Clinton C. Mason
- Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America
| | - Kieren Mather
- Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Edward Horton
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
- Joslin Diabetes Center, Boston, Massachusetts, United States of America
| | - Ronald Goldberg
- Lipid Disorders Clinic, Division of Endocrinology, Diabetes, and Metabolism, and the Diabetes Research Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States of America
| | - Dana Dabelea
- Department of Preventive Medicine and Biometrics, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States of America
| | - Steven E. Kahn
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington, United States of America
| | - Richard F. Arakaki
- Department of Medicine Clinical Research, University of Hawaii, Honolulu, Hawaii, United States of America
| | - Alan R. Shuldiner
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
| | - William C. Knowler
- Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America
| | | |
Collapse
|
89
|
Abstract
In recent decades, the prevalence of type 2 diabetes in China has increased significantly, underscoring the importance of investigating the etiological mechanisms, including genetic determinants, of the disease in Chinese populations. Numerous loci conferring susceptibility to type 2 diabetes (T2D) have been identified worldwide, with most having been identified in European populations. In terms of ethnic heterogeneity in pathogenesis as well as disease predisposition, it is imperative to explore the specific genetic architecture of T2D in Han Chinese. Replication studies of European-derived susceptibility loci have been performed, validating 11 of 32 loci in Chinese populations. Genetic investigations into heritable traits related to glucose metabolism are expected to provide new insights into the pathogenesis of T2D, and such studies have already inferred some new susceptibility loci. Other than replication studies of European-derived loci, efforts have been made to identify specific susceptibility loci in Chinese populations using methods such as genome-wide association studies. These efforts have identified additional new loci for the disease. Genetic studies can facilitate the prediction of risk for T2D and also promote individualized anti-diabetic treatment. Despite many advances in the field of risk prediction and pharmacogenetics, the pace of clinical application of these findings is rather slow. As a result, more studies into the practical utility of these findings remain necessary.
Collapse
Affiliation(s)
- Weihui Yu
- Department of Endocrinology and Metabolism, Shanghai Jiao Tong University, Shanghai, China
| | | | | |
Collapse
|
90
|
Moore SC, Gunter MJ, Daniel CR, Reddy KS, George PS, Yurgalevitch S, Devasenapathy N, Ramakrishnan L, Chatterjee N, Chanock SJ, Berndt SI, Mathew A, Prabhakaran D, Sinha R. Common genetic variants and central adiposity among Asian-Indians. Obesity (Silver Spring) 2012; 20:1902-8. [PMID: 21799482 PMCID: PMC3429696 DOI: 10.1038/oby.2011.238] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recent studies have identified common genetic variants that are unequivocally associated with central adiposity, BMI, and/or fasting plasma glucose among individuals of European descent. Our objective was to evaluate these associations in a population of Asian-Indians. We examined 16 single-nucleotide polymorphisms (SNPs) from loci previously linked to waist circumference, BMI, or fasting glucose in 1,129 Asian-Indians from New Delhi and Trivandrum. Trained medical staff measured waist circumference, height, and weight. Fasting plasma glucose was measured from collected blood specimens. Genotype-phenotype associations were evaluated using linear regression, with adjustments for age, gender, religion, and study region. For gene-environment interaction tests, total physical activity (PA) during the past 7 days was assessed by the International Physical Activity Questionnaire (IPAQ). The T allele at the FTO rs3751812 locus was associated with increased waist circumference (per allele effect of +1.58 cm, P(trend) = 0.0015) after Bonferroni adjustment for multiple testing (P(adj) = 0.04). We also found a nominally statistically significant FTO-PA interaction (P(interaction) = 0.008). Among participants with <81 metabolic equivalent (MET)-h/wk of PA, the rs3751812 variant was associated with increased waist size (+2.68 cm; 95% confidence interval (CI) = 1.24, 4.12), but not among those with 212+ MET-h/wk (-1.79 cm; 95% CI = -4.17, 0.58). No other variant had statistically significant associations, although statistical power was modest. In conclusion, we confirmed that an FTO variant associated with central adiposity in European populations is associated with central adiposity among Asian-Indians and corroborated prior reports indicating that high PA attenuates FTO-related genetic susceptibility to adiposity.
Collapse
Affiliation(s)
- Steven C Moore
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
91
|
Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen MR, Järvelin MR, Ala-Korpela M, Palotie A, de Bakker PIW. Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet 2012; 8:e1002907. [PMID: 22916037 PMCID: PMC3420921 DOI: 10.1371/journal.pgen.1002907] [Citation(s) in RCA: 148] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Accepted: 07/01/2012] [Indexed: 12/16/2022] Open
Abstract
Association testing of multiple correlated phenotypes offers better power than univariate analysis of single traits. We analyzed 6,600 individuals from two population-based cohorts with both genome-wide SNP data and serum metabolomic profiles. From the observed correlation structure of 130 metabolites measured by nuclear magnetic resonance, we identified 11 metabolic networks and performed a multivariate genome-wide association analysis. We identified 34 genomic loci at genome-wide significance, of which 7 are novel. In comparison to univariate tests, multivariate association analysis identified nearly twice as many significant associations in total. Multi-tissue gene expression studies identified variants in our top loci, SERPINA1 and AQP9, as eQTLs and showed that SERPINA1 and AQP9 expression in human blood was associated with metabolites from their corresponding metabolic networks. Finally, liver expression of AQP9 was associated with atherosclerotic lesion area in mice, and in human arterial tissue both SERPINA1 and AQP9 were shown to be upregulated (6.3-fold and 4.6-fold, respectively) in atherosclerotic plaques. Our study illustrates the power of multi-phenotype GWAS and highlights candidate genes for atherosclerosis.
Collapse
Affiliation(s)
- Michael Inouye
- Medical Systems Biology, Departments of Pathology and of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Does Familial Clustering of Risk Factors for Long-Term Diabetic Complications Leave Any Place for Genes That Act independently? J Cardiovasc Transl Res 2012; 5:388-98. [DOI: 10.1007/s12265-012-9385-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2012] [Accepted: 05/30/2012] [Indexed: 10/28/2022]
|
93
|
Rasmussen-Torvik LJ, Guo X, Bowden DW, Bertoni AG, Sale MM, Yao J, Bluemke DA, Goodarzi MO, Chen YI, Vaidya D, Raffel LJ, Papanicolaou GJ, Meigs JB, Pankow JS. Fasting glucose GWAS candidate region analysis across ethnic groups in the Multiethnic Study of Atherosclerosis (MESA). Genet Epidemiol 2012; 36:384-91. [PMID: 22508271 DOI: 10.1002/gepi.21632] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Revised: 01/27/2012] [Accepted: 02/09/2012] [Indexed: 01/21/2023]
Abstract
Genetic variants associated with fasting glucose in European ancestry populations are increasingly well understood. However, the nature of the associations between these single nucleotide polymorphisms (SNPs) and fasting glucose in other racial and ethnic groups is unclear. We sought to examine regions previously identified to be associated with fasting glucose in Caucasian genome-wide association studies (GWAS) across multiple ethnicities in the Multiethnic Study of Atherosclerosis (MESA). Nondiabetic MESA participants with fasting glucose measured at the baseline exam and with GWAS genotyping were included; 2,349 Caucasians, 664 individuals of Chinese descent, 1,366 African Americans, and 1,171 Hispanics. Genotype data were generated from the Affymetrix 6.0 array and imputation in IMPUTE. Fasting glucose was regressed on SNP dosage data in each ethnic group adjusting for age, gender, MESA study center, and ethnic-specific principal components. SNPs from the three gene regions with the strongest associations to fasting glucose in previous Caucasian GWAS (MTNR1B / GCK / G6PC2) were examined in depth. There was limited power to replicate associations in other ethnic groups due to smaller allele frequencies and limited sample size; SNP associations may also have differed across ethnic groups due to differing linkage disequilibrium patterns with causal variants. rs10830963 in MTNR1B and rs4607517 in GCK demonstrated consistent magnitude and direction of association with fasting glucose across ethnic groups, although the associations were often not nominally significant. In conclusion, certain SNPs in MTNR1B and GCK demonstrate consistent effects across four racial and ethnic groups, narrowing the putative region for these causal variants.
Collapse
Affiliation(s)
- Laura J Rasmussen-Torvik
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
94
|
Abstract
Type 2 diabetes is a complex metabolic disorder characterised by varying degrees of impairment in insulin secretion and resistance to the action of insulin. Considerable progress has been made recently in understanding the genetic determinants of diabetes. A logical next step is to describe how these variants relate to the underlying pathophysiological processes that lead to diabetes as this may provide insights into pathways to disease. These quantitative traits are, of course, of direct interest in themselves and a growing literature is now emerging on the genetic determinants of insulin secretion and insulin resistance. This review article focuses on describing the complex associations between type 2 diabetes risk variants and quantitative glycaemic traits and the relationship between variants initially discovered in association studies of these traits and risk of type 2 diabetes.
Collapse
Affiliation(s)
- Adam Barker
- Medical Research Council Epidemiology Unit, Addenbrooke's Hospital, Institute of Metabolic Science, Cambridge, UK
| | | | | |
Collapse
|
95
|
Saxena R, Elbers C, Guo Y, Peter I, Gaunt T, Mega J, Lanktree M, Tare A, Castillo B, Li Y, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight B, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm B, Braund P, Burton P, Chandrupatla H, Clarke R, Cooper-DeHoff R, Crook E, Davey-Smith G, Day I, de Boer A, de Groot M, Drenos F, Ferguson J, Fox C, Furlong C, Gibson Q, Gieger C, Gilhuijs-Pederson L, Glessner J, Goel A, Gong Y, Grant S, Grobbee D, Hastie C, Humphries S, Kim C, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaee T, Lawlor D, Li M, Lobmeyer M, Maitland-van der Zee AH, Meijs M, Molony C, Morrow D, Murugesan G, Musani S, Nelson C, Newhouse S, O'Connell J, Padmanabhan S, Palmen J, Patel S, Pepine C, Pettinger M, Price T, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith E, Spijkerman A, Stanton A, Steffes M, Thorand B, Trip M, van der Harst P, van der A D, van Iperen E, van Setten J, van Vliet-Ostaptchouk J, Verweij N, Wolffenbuttel B, Young T, Zafarmand M, Zmuda J, Boehnke M, Altshuler D, McCarthy M, Kao W, Pankow J, Cappola T, Sever P, Poulter N, Caulfield M, Dominiczak A, Shields D, Bhatt DL, Zhang L, Curtis S, Danesh J, Casas J, van der Schouw Y, Onland-Moret N, Doevendans P, Dorn G, Farrall M, FitzGerald G, Hamsten A, Hegele R, Hingorani A, Hofker M, Huggins G, Illig T, Jarvik G, Johnson J, Klungel O, Knowler W, Koenig W, März W, Meigs J, Melander O, Munroe P, Mitchell B, Bielinski S, Rader D, Reilly M, Rich S, Rotter J, Saleheen D, Samani N, Schadt E, Shuldiner A, Silverstein R, Kottke-Marchant K, Talmud P, Watkins H, Asselbergs FW, de Bakker P, McCaffery J, Wijmenga C, Sabatine M, Wilson J, Reiner A, Bowden D, Hakonarson H, Siscovick D, Keating B. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012; 90:410-25. [PMID: 22325160 PMCID: PMC3309185 DOI: 10.1016/j.ajhg.2011.12.022] [Citation(s) in RCA: 195] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Revised: 12/06/2011] [Accepted: 12/31/2011] [Indexed: 01/12/2023] Open
Abstract
To identify genetic factors contributing to type 2 diabetes (T2D), we performed large-scale meta-analyses by using a custom ∼50,000 SNP genotyping array (the ITMAT-Broad-CARe array) with ∼2000 candidate genes in 39 multiethnic population-based studies, case-control studies, and clinical trials totaling 17,418 cases and 70,298 controls. First, meta-analysis of 25 studies comprising 14,073 cases and 57,489 controls of European descent confirmed eight established T2D loci at genome-wide significance. In silico follow-up analysis of putative association signals found in independent genome-wide association studies (including 8,130 cases and 38,987 controls) performed by the DIAGRAM consortium identified a T2D locus at genome-wide significance (GATAD2A/CILP2/PBX4; p = 5.7 × 10(-9)) and two loci exceeding study-wide significance (SREBF1, and TH/INS; p < 2.4 × 10(-6)). Second, meta-analyses of 1,986 cases and 7,695 controls from eight African-American studies identified study-wide-significant (p = 2.4 × 10(-7)) variants in HMGA2 and replicated variants in TCF7L2 (p = 5.1 × 10(-15)). Third, conditional analysis revealed multiple known and novel independent signals within five T2D-associated genes in samples of European ancestry and within HMGA2 in African-American samples. Fourth, a multiethnic meta-analysis of all 39 studies identified T2D-associated variants in BCL2 (p = 2.1 × 10(-8)). Finally, a composite genetic score of SNPs from new and established T2D signals was significantly associated with increased risk of diabetes in African-American, Hispanic, and Asian populations. In summary, large-scale meta-analysis involving a dense gene-centric approach has uncovered additional loci and variants that contribute to T2D risk and suggests substantial overlap of T2D association signals across multiple ethnic groups.
Collapse
Affiliation(s)
- Richa Saxena
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Clara C. Elbers
- Department of Genetics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
- Complex Genetics Section, Department of Medical Genetics, University Medical Center Utrecht, The Netherlands
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
| | - Yiran Guo
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- BGI Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen 518083, China
| | - Inga Peter
- Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029 USA
| | - Tom R. Gaunt
- Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
| | - Jessica L. Mega
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 021155 USA
| | - Matthew B. Lanktree
- Department of Biochemistry, University of Western Ontario, London, ON N6A 5C1, Canada
| | - Archana Tare
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
| | - Berta Almoguera Castillo
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Servicio de Genética Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Avda. Reyes Católicos 228040, Madrid, Spain
| | - Yun R. Li
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Toby Johnson
- Clinical Pharmacology, Barts and the London Genome Centre, Queen Mary University of London, London EC1M 6BQ, UK
- William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | - Marcel Bruinenberg
- LifeLines Cohort Study and Biobank, University Medical Center Groningen, University of Groningen, the Netherlands
| | - Diane Gilbert-Diamond
- Children's Environmental Health and Disease Prevention Center at Dartmouth, Hanover, NH 03755, USA
- Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH 03756, USA
| | | | - Benjamin F. Voight
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
| | - Ashok Balasubramanyam
- Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
| | - John Barnard
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
| | - Florianne Bauer
- Complex Genetics Section, Department of Medical Genetics, University Medical Center Utrecht, The Netherlands
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
| | - Jens Baumert
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Tushar Bhangale
- Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
| | - Bernhard O. Böhm
- Cardiology Group Frankfurt-Sachsenhausen, Frankfurt 60598, Germany
| | - Peter S. Braund
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
| | - Paul R. Burton
- Department of Health Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK
| | - Hareesh R. Chandrupatla
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Robert Clarke
- Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX37LF, UK
| | - Rhonda M. Cooper-DeHoff
- Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
| | | | - George Davey-Smith
- Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
| | - Ian N. Day
- Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
| | - Anthonius de Boer
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - Mark C.H. de Groot
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - Fotios Drenos
- Centre for Cardiovascular Genetics, Department of Medicine, University College London, 5 University Street, London, WC1E 6JF, UK
| | - Jane Ferguson
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Caroline S. Fox
- Framingham Heart Study, Boston University School of Medicine, Boston, MA 02118, USA
| | - Clement E. Furlong
- Department of Medicine (Medical Genetics), University of Washington, Seattle, WA 98195, USA
- Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
| | - Quince Gibson
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Christian Gieger
- Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Lisa A. Gilhuijs-Pederson
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - Joseph T. Glessner
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Anuj Goel
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
| | - Yan Gong
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
| | - Struan F.A. Grant
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Diederick E. Grobbee
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
| | - Claire Hastie
- British Heart Foundation Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow G12 8TA, UK
| | - Steve E. Humphries
- Centre for Cardiovascular Genetics, Department of Medicine, University College London, 5 University Street, London, WC1E 6JF, UK
| | - Cecilia E. Kim
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Mika Kivimaki
- Department of Epidemiology and Public Health, University College London, London, UK
- Genetic Epidemiology Group, Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK
| | - Marcus Kleber
- LURIC Study, Freiburg im Breisgau 79098, Germany
- Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg 69037, Germany
| | - Christa Meisinger
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Meena Kumari
- Genetic Epidemiology Group, Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK
| | - Taimour Y. Langaee
- Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
| | - Debbie A. Lawlor
- Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
| | - Mingyao Li
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Maximilian T. Lobmeyer
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
| | - Anke-Hilse Maitland-van der Zee
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - Matthijs F.L. Meijs
- Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Cliona M. Molony
- Department of Genetics, Rosetta Inpharmatics, Seattle, WA 98109, USA
| | - David A. Morrow
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 021155 USA
| | - Gurunathan Murugesan
- Department of Clinical Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH 44106, USA
| | - Solomon K. Musani
- Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
| | - Christopher P. Nelson
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
| | - Stephen J. Newhouse
- Clinical Pharmacology, Barts and the London Genome Centre, Queen Mary University of London, London EC1M 6BQ, UK
- William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | - Jeffery R. O'Connell
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Sandosh Padmanabhan
- British Heart Foundation Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow G12 8TA, UK
| | - Jutta Palmen
- Centre for Cardiovascular Genetics, Department of Medicine, University College London, 5 University Street, London, WC1E 6JF, UK
| | - Sanjey R. Patel
- Division of Sleep Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Carl J. Pepine
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
| | - Mary Pettinger
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Thomas S. Price
- Medical Research Council Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London WC2R 2LS, UK
| | - Suzanne Rafelt
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
| | - Jane Ranchalis
- Department of Medicine (Medical Genetics), University of Washington, Seattle, WA 98195, USA
| | - Asif Rasheed
- Center for Non-Communicable Diseases, Karachi, Pakistan
| | - Elisabeth Rosenthal
- Department of Medicine (Medical Genetics), University of Washington, Seattle, WA 98195, USA
| | - Ingo Ruczinski
- Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Sonia Shah
- University College Genetics Institute, University College London, 5 University St London, WC1E 6BT, UK
| | - Haiqing Shen
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Günther Silbernagel
- Division of Endocrinology, Diabetology, Nephrology, Vascular Disease, and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls-University Tübingen, Tübingen 72074, Germany
| | | | | | - Alice Stanton
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - Michael W. Steffes
- Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN 55455, USA
| | - Barbara Thorand
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Mieke Trip
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Pim van der Harst
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- Department of Genetics, University Medical Center Groningen and Groningen University, 9700 RB Groningen, The Netherlands
| | - Daphne L. van der A
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | | | - Jessica van Setten
- Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jana V. van Vliet-Ostaptchouk
- Molecular Genetics, Department of Pathology and Medical Biology, University Medical Center Groningen and University of Groningen, The Netherlands
- Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Niek Verweij
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Bruce H.R. Wolffenbuttel
- Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Taylor Young
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
| | - M. Hadi Zafarmand
- Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Joseph M. Zmuda
- Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto St, Pittsburgh, PA 15261, USA
| | | | | | - Michael Boehnke
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
| | - David Altshuler
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
- Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - Mark McCarthy
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | - W.H. Linda Kao
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21287, USA
| | - James S. Pankow
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA
| | - Thomas P. Cappola
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Peter Sever
- International Centre for Circulatory Health, Imperial College London, London W2 1PG, UK
| | - Neil Poulter
- International Centre for Circulatory Health, Imperial College London, London W2 1PG, UK
| | - Mark Caulfield
- Clinical Pharmacology, Barts and the London Genome Centre, Queen Mary University of London, London EC1M 6BQ, UK
- William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | - Anna Dominiczak
- British Heart Foundation Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow G12 8TA, UK
| | - Denis C. Shields
- Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
| | | | - Li Zhang
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
| | - Sean P. Curtis
- Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA
| | - John Danesh
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
| | - Juan P. Casas
- Department of Epidemiology and Public Health, University College London, London, UK
- Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - Yvonne T. van der Schouw
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
| | - N. Charlotte Onland-Moret
- Complex Genetics Section, Department of Medical Genetics, University Medical Center Utrecht, The Netherlands
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
| | - Pieter A. Doevendans
- Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gerald W. Dorn
- Washington University Center for Pharmacogenetics, 660 S. Euclid Ave, Campus Box 8220, St. Louis, MO 63110, USA
| | - Martin Farrall
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
- Department of Cardiovascular Medicine, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
| | - Garret A. FitzGerald
- The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, PA 19146, USA
| | - Anders Hamsten
- Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden
| | - Robert Hegele
- Department of Biochemistry, University of Western Ontario, London, ON N6A 5C1, Canada
| | - Aroon D. Hingorani
- Centre for Clinical Pharmacology, Department of Medicine, University College London, London WC1E 6JF, UK
| | - Marten H. Hofker
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Gordon S. Huggins
- Molecular Cardiology Research Institute, Center for Translational Genomics, Tufts Medical Center and Tufts University, Boston, MA 02114, USA
| | - Thomas Illig
- Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
- Hannover Unified Biobank, Hannover Medical School, 30625 Hannover, Germany
| | - Gail P. Jarvik
- Department of Medicine (Medical Genetics), University of Washington, Seattle, WA 98195, USA
| | - Julie A. Johnson
- Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
| | - Olaf H. Klungel
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
| | - William C. Knowler
- National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ 85104, USA
| | - Wolfgang Koenig
- Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
| | - Winfried März
- Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg 69037, Germany
- Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg D-68167 Mannheim, Germany
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8010 Graz, Austria
| | - James B. Meigs
- Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA
- General Medicine Division, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Olle Melander
- Clinical Research Center, Malmö University Hospital, Malmö SE-205 02, Sweden
| | - Patricia B. Munroe
- Clinical Pharmacology, Barts and the London Genome Centre, Queen Mary University of London, London EC1M 6BQ, UK
- William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | - Braxton D. Mitchell
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Susan J. Bielinski
- Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | - Daniel J. Rader
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Muredach P. Reilly
- Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Stephen S. Rich
- Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22902, USA
| | - Jerome I. Rotter
- Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Danish Saleheen
- Center for Non-Communicable Diseases, Karachi, Pakistan
- Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA
| | - Nilesh J. Samani
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
| | | | - Alan R. Shuldiner
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Roy Silverstein
- Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 9500 Euclid Avenue Cleveland, OH 44195, USA
| | | | - Philippa J. Talmud
- Centre for Cardiovascular Genetics, Department of Medicine, University College London, 5 University Street, London, WC1E 6JF, UK
| | - Hugh Watkins
- Washington University Center for Pharmacogenetics, 660 S. Euclid Ave, Campus Box 8220, St. Louis, MO 63110, USA
| | - Folkert W. Asselbergs
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
- Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Paul I.W. de Bakker
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA
- Complex Genetics Section, Department of Medical Genetics, University Medical Center Utrecht, The Netherlands
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
- Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Jeanne McCaffery
- Weight Control and Diabetes Research Center, The Miriam Hospital and Warren Alpert School of Medicine at Brown University, Providence, RI 02906, USA
| | - Cisca Wijmenga
- Department of Genetics, University Medical Center Groningen and Groningen University, 9700 RB Groningen, The Netherlands
| | - Marc S. Sabatine
- Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 021155 USA
| | - James G. Wilson
- Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
| | - Alex Reiner
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Donald W. Bowden
- Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC 27106, USA
| | - Hakon Hakonarson
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - David S. Siscovick
- Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA 98101, USA
| | - Brendan J. Keating
- Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| |
Collapse
|
96
|
A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels. PLoS One 2012; 7:e32327. [PMID: 22403646 PMCID: PMC3293812 DOI: 10.1371/journal.pone.0032327] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2011] [Accepted: 01/25/2012] [Indexed: 11/19/2022] Open
Abstract
Haptoglobin is an acute phase inflammatory marker. Its main function is to bind hemoglobin released from erythrocytes to aid its elimination, and thereby haptoglobin prevents the generation of reactive oxygen species in the blood. Haptoglobin levels have been repeatedly associated with a variety of inflammation-linked infectious and non-infectious diseases, including malaria, tuberculosis, human immunodeficiency virus, hepatitis C, diabetes, carotid atherosclerosis, and acute myocardial infarction. However, a comprehensive genetic assessment of the inter-individual variability of circulating haptoglobin levels has not been conducted so far. We used a genome-wide association study initially conducted in 631 French children followed by a replication in three additional European sample sets and we identified a common single nucleotide polymorphism (SNP), rs2000999 located in the Haptoglobin gene (HP) as a strong genetic predictor of circulating Haptoglobin levels (Poverall = 8.1×10−59), explaining 45.4% of its genetic variability (11.8% of Hp global variance). The functional relevance of rs2000999 was further demonstrated by its specific association with HP mRNA levels (β = 0.23±0.08, P = 0.007). Finally, SNP rs2000999 was associated with decreased total and low-density lipoprotein cholesterol in 8,789 European children (Ptotal cholesterol = 0.002 and PLDL = 0.0008). Given the central position of haptoglobin in many inflammation-related metabolic pathways, the relevance of rs2000999 genotyping when evaluating haptoglobin concentration should be further investigated in order to improve its diagnostic/therapeutic and/or prevention impact.
Collapse
|
97
|
Ryu J, Lee C. Association of glycosylated hemoglobin with the gene encoding CDKAL1 in the Korean Association Resource (KARE) study. Hum Mutat 2012; 33:655-9. [DOI: 10.1002/humu.22040] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 01/13/2012] [Indexed: 01/07/2023]
|
98
|
Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikäinen LP, Kangas AJ, Soininen P, Würtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kähönen M, Lehtimäki T, Pietiläinen KH, Inouye M, McCarthy MI, Jula A, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Järvelin MR, Peltonen L, Perola M, Freimer NB, Ala-Korpela M, Palotie A, Ripatti S. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012; 44:269-76. [PMID: 22286219 PMCID: PMC3605033 DOI: 10.1038/ng.1073] [Citation(s) in RCA: 420] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2011] [Accepted: 12/13/2011] [Indexed: 12/12/2022]
Abstract
Nuclear magnetic resonance assays allow for measurement of a wide range of metabolic phenotypes. We report here the results of a GWAS on 8,330 Finnish individuals genotyped and imputed at 7.7 million SNPs for a range of 216 serum metabolic phenotypes assessed by NMR of serum samples. We identified significant associations (P < 2.31 × 10(-10)) at 31 loci, including 11 for which there have not been previous reports of associations to a metabolic trait or disorder. Analyses of Finnish twin pairs suggested that the metabolic measures reported here show higher heritability than comparable conventional metabolic phenotypes. In accordance with our expectations, SNPs at the 31 loci associated with individual metabolites account for a greater proportion of the genetic component of trait variance (up to 40%) than is typically observed for conventional serum metabolic phenotypes. The identification of such associations may provide substantial insight into cardiometabolic disorders.
Collapse
Affiliation(s)
- Johannes Kettunen
- Institute for Molecular Medicine Finland, University of Helsinki, Finland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
99
|
Abstract
The global epidemic of type 2 diabetes mellitus (T2D) is one of the most challenging problems of the 21(st) century leading cause of and the fifth death worldwide. Substantial evidence suggests that T2D is a multifactorial disease with a strong genetic component. Recent genome-wide association studies (GWAS) have successfully identified and replicated nearly 75 susceptibility loci associated with T2D and related metabolic traits, mostly in Europeans, and some in African, and South Asian populations. The GWAS serve as a starting point for future genetic and functional studies since the mechanisms of action by which these associated loci influence disease is still unclear and it is difficult to predict potential implication of these findings in clinical settings. Despite extensive replication, no study has unequivocally demonstrated their clinical role in the disease management beyond progression to T2D from impaired glucose tolerance. However, these studies are revealing new molecular pathways underlying diabetes etiology, gene-environment interactions, epigenetic modifications, and gene function. This review highlights evolving progress made in the rapidly moving field of T2D genetics that is starting to unravel the pathophysiology of a complex phenotype and has potential to show clinical relevance in the near future.
Collapse
|
100
|
Liu DJ, Leal SM. A flexible likelihood framework for detecting associations with secondary phenotypes in genetic studies using selected samples: application to sequence data. Eur J Hum Genet 2011; 20:449-56. [PMID: 22166943 DOI: 10.1038/ejhg.2011.211] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
For most complex trait association studies using next-generation sequencing, in addition to the primary phenotype of interest, many clinically important secondary traits are also available, which can be analyzed to map susceptibility genes. Owing to high sequencing costs, most studies use selected samples, and the sampling mechanisms of these studies can be complicated. When the primary and secondary traits are correlated, analyses of secondary phenotypes can cause spurious associations in selected samples and existing methods are inadequate to adjust for them. To address this problem, a likelihood-based method, MULTI-TRAIT-ASSOCIATION (MTA) was developed. MTA is flexible and can be applied to any study with known sampling mechanisms. It also allows efficient inferences of genetic parameters. To investigate the power of MTA and different study designs, extensive simulations were performed under rigorous population genetic and phenotypic models. It is demonstrated that there are great benefits for analyzing secondary phenotypes in selected samples. In particular, using case-control samples and samples with extreme primary phenotypes can be more powerful than analyzing random samples of equivalent size. One major challenge for sequence-based association studies is that most data sets are not of sufficient size to be adequately powered. By applying MTA, data sets ascertained under distinct mechanisms or targeted at different primary traits can be jointly analyzed to map common phenotypes and greatly increase power. The combined analysis can be performed using freely available data sets from public repositories, for example, dbGaP. In conclusion, MTA will have an important role in dissecting the etiology of complex traits.
Collapse
Affiliation(s)
- Dajiang J Liu
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | | |
Collapse
|